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1.1 INTRODUCTION 
 
Clinical features 
 
Simpson-Golabi-Behmel syndrome (SGBS) is an X-linked skeletal overgrowth disorder. The 
exact prevalence of SGBS is unknown, but it is believed to be under-diagnosed1. By 2005 at 
least 130 patients had been reported on worldwide2.  
This disorder is characterised by pre- and postnatal macrosomia. Facial features are 
described as being “coarse”. Distinctive facial features are those of an upturned nose, 
hypertelorism and downslanting palpebral fissures. Other manifestations such as 
macrostomia, macroglossia and a midline groove in the lower lip or tongue are often present. 
Less commonly cleft lip and palate can also occur. Supernumerary nipples are frequent. 
Short hands and feet with poly- or syndactyly have also been reported3. 
Structural abnormalities include umbilical and diaphragmatic hernias as well as genitourinary 
defects3. Cardiac abnormalities are present in 36% of patients with SGBS4. Skeletal 
abnormalities include vertebral fusion, scoliosis, pectus excavatum and rib anomalies1. 
Development can be normal, or mildly delayed3.  
Persons with SGBS have a 10% risk of developing embryonal tumours, and tumour 
surveillance is necessary. The tumours described in SGBS are Wilms tumour, 
hepatoblastoma, adrenal neuroblastoma, gonadal blastoma and hepatocellular carcinoma5.  
Carrier females can have mild manifestations of SGBS due to skewed X-inactivation6. Other 
possible reasons for females manifesting signs of SGBS are numerical X-chromosome 
abnormalities (e.g. Turner syndrome), X-autosome translocations, and the presence of 
mutations on both X-chromosomes. The features of SGBS can range from minimal, such as 
a large mouth and coarse facies with normal intelligence; to more severe signs such as 
developmental delay, cardiac abnormalities, and macrosomia6.  
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Medical genetics and genetic counselling 
 
SGBS is an X-linked recessive disorder and males with the mutation will manifest the 
phenotype, whereas women with the mutation are termed “carriers”, and are usually 
clinically unaffected. When a woman carrying this mutation has a child, she would have a 
50% chance of passing the abnormal X-chromosome in each pregnancy. She would thus 
have a 25% chance of having an affected son, and a 25% chance of having a carrier 
daughter. 
 
Molecular genetics 
 
Mutations in two genes, glypican 3 (GPC3) and the adjacent glypican 4 (GPC4) have been 
reported to be responsible for SGBS.  
The GPC3 gene at Xq26 spans 500kb of genomic DNA and consists of eight exons. GPC3 
encodes glypican 3, a cell surface heparan sulfate proteoglycan, that plays a role in cell 
growth and division.  Mutations in GPC3 that cause SGBS can be deletions or point 
mutations, both of which cause loss of function of the GPC3 product.  There are no known 
hotspots for mutations. Most point mutations occur in exon 3 (the largest exon), and 50% of 
deletions occur in exon 87. Results of studies investigating the detection rate of GPC3 
mutation in patients with SGBS vary greatly.  Some studies report detection rates of 37%8, 
whereas others have rates as high as 70%7.  
The GPC4 gene, also at Xq26, is adjacent to the 3‟ end of GPC3. Previously, a deletion 
involving the 3‟ end of GPC3 and spanning GPC4 was described in a patient with SGBS7. 
Loss of function of GPC4, without involvement of GPC3 has not been reported to cause 
SGBS. However, recently a duplication of GPC4 has been found in a family with SGBS9. For 
the purpose of this study, GPC4 will not be investigated.  
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1.2 JUSTIFICATION 
 
No studies from South Africa relating to SGBS could be found during a Pubmed, and Google 
scholar search. Key words used were “Simpson-Golabi-Behmel syndrome and South Africa”. 
Diagnostic testing for SGBS is not currently available in South Africa. The diagnosis of 
SGBS is made on clinical examination, unless a disease causing mutation can be identified.  
Careful review of medical records and examination of the two affected probands will help by 
identifying frequent clinical features, in turn this will facilitate diagnosis in the future as it is 
generally accepted that SGBS is under-diagnosed. Careful delineation and comparison of a 
clinical phenotype to reports in the literature would also help with diagnosis of affected 
persons in the future.  
Analysis and sequencing of GPC3 has the potential to confirm a clinical diagnosis. If a 
disease causing mutation is found, it would be appropriate to go on to determine whether or 
not the affected male‟s mother is a gene mutation carrier. Knowing the mother‟s carrier 
status will firstly clarify her risk of having another affected son or carrier daughter. Secondly, 
it will have implications for the family as other members could potentially be mutation carriers 
and at risk of having a boy with SGBS.  
Establishing the technology for SGBS testing in this study could potentially result in future 
diagnostic testing for South Africa, if it is found to be cost effective. 
 
1.3 AIM 
 
The identification of a disease causing mutation in two families with a clinical diagnosis of 
Simpson-Golabi-Behmel syndrome. 
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1.4 OBJECTIVES 
 
The objectives of this study will be as follows: 
1. Describing the phenotype of two male probands, with a clinical diagnosis of Simpson-
Golabi-Behmel syndrome, and their family members. 
2. Molecular analysis of the GPC3 gene using DNA from the affected probands in an 
attempt to isolate a disease-causing mutation.  
 
1.5 METHODS 
 
1.5.1 Study design 
 
This study is a case series with a clinical and a molecular component 
 
1.5.2 Subject identification  
 
Two male probands in different families (proband B and S) seen by the Division of Human 
Genetics, University of Cape Town were identified following a diagnosis of SGBS made 
during clinical evaluation. These two young boys will form the starting point for this study. 
The two boys and their respective mothers will be clinically re-examined and examined in 
conjunction with members of the Genetics team. Proband S has a maternal aunt reported to 
have intellectual difficulties and she, as well as his maternal grandmother will also be 
examined if possible. This approach will be undertaken as both these women are at risk of 
being carriers, and could manifest some signs of SGBS. 
 
1.5.3 Recruitment and Enrolment 
 
Proband B was identified when a referral was made to the Division of Human Genetics from 
Groote Schuur Hospital. Proband S was seen at the Genetic Clinic at Red Cross War 
Memorial Children‟s Hospital as an outpatient.  
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During a previous consultation the mother of proband B was informed of the possibility of 
genetic testing to confirm a diagnosis in her son, in which she expressed a keen interest.  
Both probands‟ mothers will be personally informed regarding the research project during a 
scheduled visit to the Division of Human Genetics.  
Both mothers will be invited to participate in the study. The mother of proband S will be 
asked to invite her sister and mother to the information giving session. These family 
members will also be invited to participate in the research study.  
Their participation will be voluntary and subject to informed consent. 
 
1.5.4 Measurements and methods 
 
Inclusion criteria for patients into the study: 
 
Boys clinically affected with SGBS 
Mothers of affected boys 
Family members with intellectual or medical difficulties related via a maternal line 
Unaffected male sibling of affected male 
Availability for clinical examination 
 
1.5.4.1 Case series study - clinical component:   
 
This part of the study will involve re-examination of the patients and their relevant family 
members. Pedigrees will also be obtained during this process. A data capture sheet will be 
designed to help facilitate information gathering.  Medical records will be reviewed. 
(appendices 1 and 2)  
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1.5.4.2 Case series study – molecular component: 
 
This part of the study will be carried out in the University of Cape Town, Division of Human 
Genetics laboratory.  
a) DNA extraction 
DNA will be extracted from participants‟ peripheral blood or saliva samples. DNA from an 
unaffected male sibling will also be extracted from saliva if he and his mother agree to 
participation. DNA will be extracted from blood using a salting out method, according to the 
laboratory operating protocol. DNA from saliva will be extracted using DNA genotek 
extraction kit.  
b) Primer design and PCR 
Each of the eight exons of GPC3 will be amplified during a Polymerase Chain reaction 
(PCR) using primer pairs. Exons 1-8 will be amplified using forward and reverse primers that 
have previously been described by Sakazume et al. Exon 3 will be amplified with an 
additional internal primer pair due to the large size of this exon10. These primers were 
designed to overlap the intron exon boundary. The primers were checked for amplification 
specificity and stability. 
c) Mutation identification 
The PCR amplification products will initially be run on an agarose gel. If a whole exon 
deletion is present there will be no band visible on the agarose gel. A control sample will also 
be used as this will confirm whether the PCR amplification process was successful. The 
control samples that will be used will be that of an unrelated, unaffected male, and proband 
S‟s unaffected brother (if consent is obtained). If a whole exon deletion is found to be 
present, a literature search using PUBMED will be undertaken to confirm that this deletion 
has previously been reported and is thus disease-causing.  If this is found to be disease-
causing further analysis of at risk family members will be undertaken, starting with the 
relevant mother.  
If no obvious deletion is identified the PCR products will be sequenced using a sequencing 
kit and then analysed using an ABI 3130 sequence analyser. If a mutation is identified it will 
be investigated by comparison with an unaffected male reference sample. It will also be 
referenced against literature reports on known mutations in SGBS and compared to 
bioinformatics databases to assess putative implications. If it is found to be disease-causing 
further investigation of at risk family members will be undertaken.  
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If no obvious mutation is found during sequencing the diagnosis can neither be confirmed 
nor refuted.  
(appendices 3 and 4 illustrate flow diagrams explaining the methodology) 
 
1.5.5 Analysis 
 
A careful description of relevant clinical features will be presented and compared with other 
family members and previously reported patients. 
Molecular findings will be analysed by using software programs. The results will then be 
compared to the current reference sequence of GPC3 on the NCBI website.  
 
1.6 ETHICS 
 
Written informed consent will be obtained from all participants. The home languages of the 
participants are English and Afrikaans and informed consent will be available in both these 
languages. In the case of minors, consent will be obtained from their parents and where 
possible assent will be obtained from children. An information sheet will also be given to all 
participants to take home. (appendices 5, 6 and 7) 
All information will be stored in password protected computers. Written information will be 
stored in a locked office.   
All personal identifiers will be changed if the data is published. Photographs will only be used 
with the eyes hidden and with informed consent.   
There is no significant risk of physical harm during this study. No other genes or genetic 
information, other than that related to SGBS, will be analysed.  
Participation in the study will be on a voluntary basis. Should any participants wish to 
discontinue their involvement in the study they could do so at any time.  
Contact details of the researcher and the supervisor will be supplied on the information 
sheet. 
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The results of the analysis and the implications thereof will be conveyed to the families, 
either personally or telephonically if a face to face consultation is not possible. 
All efforts will be made to inform participants of results.  
Ethics approval from the Research Ethics Committee of the University of Cape Town will be 
sought. 
 
1.7 LOGISTICS 
 
Table 1.1: Planned time frame of project 
Protocol writing December 2011  
Ethics submission January  2012 
Literature review December 2011 – January 2012 
Clinical information gathering February  2012 – March 2012 
Molecular laboratory work March 2012 – May 2012 
Analysis of data May 2012 – June 2012 
Write up July 2012 – September 2012 
Submission October 2012 
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1.8 BUDGET 
 
National Research Foundation funds are available for the project. (appendix 8 for the funding 
application) 
Table 1.2:  Proposed budget for research project 
MOLECULAR INVESTIGATIONS:  
Extraction DNA                                                      R 500.00 
Primers for amplifying exons                                                      R 5000.00  
PCR                                                      R 500.00                      
Sequencing R 10 000.00 
MISCELLANEOUS:  
Printing and binding                                                     R 600.00 
Miscellaneous                                                R 400.00 
  
PROPOSED BUDGET TOTAL: R 17 000.00 
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2.1 OBJECTIVES 
 
The objective of the study was to investigate two boys with Simpson-Golabi-Behmel 
syndrome (SGBS)[OMIM #312870]. The clinical features in these boys were documented 
and investigations were undertaken to identify the molecular mutation causing the disorder in 
the two families. 
The main objectives of this literature review are: 
 To find reports that describe the clinical features of SGBS. 
 To ascertain whether there are any population specific differences in the clinical 
presentation of SGBS 
 To investigate the genetic basis and inheritance of SGBS 
 To review the methods through which a molecular diagnosis can be made in this 
condition. 
 
2.2 LITERATURE SEARCH STRATEGY 
 
An internet search was undertaken using the PUBMED database. The search was broadly 
divided into two parts. The first part related to the clinical presentation, and the second part 
was focused on the genetic transmission and molecular basis of the disorder.   
In the clinical part of the internet search the following phrases were used:  
 “Simpson Golabi Behmel AND clinical” 
“Simpson Golabi Behmel AND diagnostic features” 
“Simpson Golabi Behmel AND diagnostic criteria” 
The first search produced 40 reports, and the second only 12. No reports were found for the 
third search criteria. 
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The literature was included or rejected according to the following criteria. 
Inclusion criteria: 
 Studies describing the clinical features of affected persons. 
 Recent review articles 
 Articles written in English 
The first study describing SGBS was published in 1975. For this reason there were no 
specific inclusion or exclusion criteria relating to timing of publishing.   
Exclusion criteria: 
 Studies describing the clinical features of Simpson-Golabi-Behmel syndrome type 2. 
This condition is sometimes referred to as the lethal variant of SGBS. The causative 
mutation in this syndrome maps to a different genetic locus (Xp22)1,2 and is 
presumed to be a distinct disorder3.  
In the search addressing the molecular genetic basis of SGBS the following phrases were 
used: 
“Simpson Golabi Behmel AND molecular” 
“Simpson Golabi Behmel AND GPC3” 
“Simpson Golabi Behmel AND GPC4” 
The first search produced 53 articles, and the second 73. The search for “Simpson Golabi 
Behmel AND GPC4” yielded only 11 articles. 
Inclusion criteria: 
 All data published from 1996 and onward. The gene responsible for SGBS was 
identified in this year. 
 Only studies describing GPC3 and GPC4 in relation to SGBS were included. 
Exclusion criteria: 
 Studies relating solely to animal subjects 
 Studies describing only the function of GPC3 and GPC4.  
 Studies describing the molecular basis of Simpson-Golabi-Behmel syndrome type 
2.(see above for rationale) 
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Neither clinical nor molecular studies describing South African patients with SGBS could be 
found on PUBMED. 
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2.3 LITERATURE REVIEW 
2.3.1 Introduction 
 
Simpson-Golabi-Behmel syndrome (SGBS) is an X-linked congenital abnormality overgrowth 
syndrome. The condition was described for the first time in 1975 by Simpson et al who 
described their patients as having “bulldoglike” facies, with a wide nasal bridge and 
anteverted nares4. Behmel et al commented that these boys had a wide mouth and 
protruding tongue, with a midline depression in the lower lip. The affected individuals had a 
protruding maxilla and broad hands. X-linked inheritance was suggested as the affected 
individuals were boys, born to unaffected mothers5.   
In January 1984 Golabi and Rosen published an article in which they described four males 
with multiple congenital abnormalities and mental retardation. These individuals had prenatal 
macrosomia and shared similar facial features such as a short broad upturned nose, a large 
mouth with a groove in the lower lip and a cleft palate. They also had skeletal abnormalities 
and various renal, cardiac and gastrointestinal malformations.  The authors postulated that it 
was a previously undescribed syndrome6. 
A short while after this article was published, Behmel et al5 reported on 13 males with 
increased birth length and weight, together with short hands and feet. The typical features 
these authors described were coarse facies, short upturned nose, wide open mouth with a 
large tongue and midline depression of the lip, and a prominent jaw. Normal intelligence was 
reported in all their living patients. In their discussion it was mentioned that although their 
cases shared similar facies to those previously described by Simpson and by Golabi and 
Rosen, there were differences in terms of certain features and intelligence5.  
In 1988 Neri et al suggested that all three of the above papers described the same 
syndrome and coined the term “Simpson-Golabi-Behmel syndrome”7. The exact prevalence 
of SGBS is unknown, but it is universally accepted that this condition is under-diagnosed3.  
This may be because SGBS is a relatively newly described syndrome together with a lack of 
commercially available molecular testing. Furthermore, it is primarily a clinical diagnosis and 
there is considerable phenotypic overlap with other overgrowth syndromes8. Nevertheless, 
at least 130 cases have been documented in the literature9. 
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The recognition and diagnosis of patients with SGBS is important because: 
 Affected boys have an increased risk of embryonal tumour development and need 
surveillance5,10. 
 People with SGBS are at risk of cardiac, genito-urinary and gastrointestinal 
complications. Skeletal and developmental abnormalities also occur11. 
 Identifying the disorder can help to determine the recurrence risks in siblings and in 
the family. 
 
2.3.2 Clinical features 
 
The diagnosis of SGBS is based on clinical manifestations. These features can be variable 
and difficult to identify but the diagnosis warrants consideration in the presence of a 
distinctive facies, multiple abnormalities and overgrowth12. 
In only one of the articles reviewed have diagnostic criteria been used to assist in defining 
the cohort that the authors were studying. In this report the males with overgrowth and at 
least two additional traits were considered as having SGBS. The additional features were: 
 Characteristic facial appearance 
 Hand anomalies 
 Skeletal abnormalities 
 Accessory nipples 
 X-linked inheritance pattern13 
Antenatal findings 
 
Prenatal ultrasound investigation has facilitated the ability to make a prenatal diagnosis of 
SGBS. This condition is one of a few overgrowth disorders that present antenatally with 
macrosomia. There are, however, other features that may help in distinguishing SGBS from 
the other overgrowth disorders. Antenatal findings that have been reported in association 
with SGBS are increased nuchal translucency, congenital diaphragmatic hernia, 
visceromegaly, postaxial polydactyly and a single umbilical artery. Renal abnormalities 
including enlarged kidneys, hydronephrosis and hydroureters have also previously been 
reported14,15. When macrosomia and any of these abnormalities are found together with 
polyhydramnios and an elevated maternal serum alpha feto protein (msAFP), SGBS 
warrants consideration15. 
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Growth parameters 
 
Macrosomia is a common feature of SGBS. This parameter is defined as a birth weight and 
height greater than the 97th centile for gestational age. Pre- and postnatal overgrowth occur 
in SGBS9.  The final adult height is often more than 2 m, depending on parental height7. 
Facial features 
 
In the papers describing the first boys with SGBS they were said to have a broad and stocky 
appearance. Their facial appearance was described as coarse, with hypertelorism and a 
broad nasal bridge6. The jaw and maxilla were prominent, and the mouth wide and open with 
a groove in the lower lip6. The nose was short and upturned. Submucous palatal clefts and 
bifid uvula were mentioned6.  
In the articles following these original descriptions, the typical SGBS facies is consistently 
described as coarse. People with SGBS have hypertelorism with a heavy brow, 
downslanting palpebral fissures and epicanthic folds 7,8,9,12,14,16,17,18. 
The nose is short, and upturned7,9,14,18. Affected boys often have macrostomia with a groove 
in either the tongue or the lower lip7,8,9,11,12,18,19. In the original descriptions macroglossia was 
not mentioned, but several later observations include macroglossia as a feature of SGBS 
7,8,9,12,13,14,16,17,18,19,20. Dental malocclusion can occur due to the macroglossia17,18. The 
prognathism which was originally described is also mentioned in later reports. 
Ear abnormalities described vary and include low set ears, thick auricles and creased 
lobes9,14,17,20 .  
Cleft lip and palate are present in about 25% of affected persons20. Other palatal 
abnormalities were mentioned in some studies, notably a high arched 5,10,12,16,20,21 or narrow 
palate9.   
Other associated abnormalities 
 
Multiple other abnormalities have been described in association with SGBS. Short, broad 
hands with polydactyly, cardiac defects, hernias and variable skeletal abnormalities have all 
been documented. Genito-urinary and gastrointestinal anomalies occur. Intellectual capacity 
is variable5,6. 
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The malformations that have been described in the case reports which have been reviewed 
are summarised in table 2.1.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 2.1: Clinical features described in literature. 
    Key:  ⨳pes planus, broad halluces, pes varus    ⁰ Uretrohydronephrosis, large kidney   √diaphragmatic and umbilical
 
 
Gurrieri 
et al 
2011
10 
Ratbi et al 
2010
18 
Lindsay et 
al 1997
11 
Griffith et 
al 2009
17 
Rodriguez-
Criado et al 
2005
9 
Li et al 
2001
13 
Mariani et al 
2003
20 
Okamoto et 
al 1999
12 
Young et al 
2006
16 
Yano et al 
2011
14 
Supernumerary 
nipples 
Yes Yes  3/3  4/6 3/6  Yes   0/2  
Cardiac 
Patent 
foramen 
ovale 
Normal 
8/18 with 
abnormality 
3/3 Normal  
1/6 pulmonary 
hypertension with 
right ventricular 
hypertrophy 
1/7 cardiac 
abnormality 
Tricuspid valve 
anomaly 
  
1/2 ventriculo-
septal defect 
Renal Normal Normal 
7/18 with 
abnormality 
3/3 Normal 
2/6 
abnormalities⁰ 
4/7 
abnormalities 
Nephromegaly   
2/2 
Nephromegaly 
and 
hydronephrosis 
Digital 
Short 
fingers, 
mild 
webbing 
Postaxial 
polydactyly 
 
3/3 Broad 
fingertips 
1/6 short hands 
5/7 hand 
anomalies 
Prominent and 
splayed 
fingertips with 
bilateral simian 
creases 
 
Broad flat 
hands 
2/2 Large 
Feet Normal    3/6 abnormal⨳  Pes planus  
Lateral 
deviation 
toes 
 
Skeletal 
abnormalities 
  
9/18 abnor-
malities 
 
1/6 pectus 
carinatum 
3/7  
Supernumerary 
rib and pectus 
excavatum 
  
2/2 pectus 
excavatum and 
rib/vertebral 
abnormalities 
CNS 
abnormalities 
 None 
2/18 
patients with 
abnormality 
 
1/6 corpus 
callosum 
agenesis 
 
Large adeno-
hypophysis  
 
Hydroce-
phalus 
 
Genitourinary 
abnormalities 
 
Undescen-
ded testes 
 
3/3 
undescen-
ded testes 
1/3 
penoscrotal 
hypo-
spadias 
 
1/7 inguinal 
hernia 
Undescended 
testes 
Inguinal 
hernia 
Inguinal 
hernia 
1/2 hydrocele 
Gastrointestinal 
abnormalities 
 Normal   
1/6 
hepatospleno-
megaly 
3/6 hernias √ 
Hepatospleno-
megaly  
Congenital 
diaphragmatic 
hernia 
Umbilical 
hernia 
 
Development 
Mild 
delay 
 
17/18 
patients 
delayed 
1/3 motor 
delay 
2/6 motor delays 
2/6 
developmen-
tal delay 
Normal  
Severe 
developmen-
tal delay 
2/2 speech and 
motor delay 
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Syndromic features of SGBS consistently reported in the literature are outlined below. 
Skeletal anomalies 
 
The hands can show brachy-, campto- or clinodactyly. Varying degrees of postaxial poly- 
and syndactyly of the hands and feet can be present 7,8. The hands and feet are often short 
and broad 7,16.   
Vertebral abnormalities and scoliosis of the spine may occur as does pectus excavatum 8.  
Gastro-intestinal anomalies 
 
Organomegaly and various intestinal malformations such as malrotation, pyloric rings and 
Meckel‟s diverticulum have been described. Diaphragmatic and umbilical hernias as well as 
omphaloceles may be present 7,8,10,17.  
Renal anomalies 
 
Enlarged, hydronephrotic, cystic or dysplastic kidneys can occur7,8,13. Renal abnormalities 
may be detected antenatally. This finding in the presence of overgrowth can lead to the 
inclusion of SGBS in the differential diagnosis.  
Genito-urinary anomalies 
 
Minor genital abnormalities are common. These include cryptorchidism and inguinal hernias. 
Hypospadias and ambiguous genitalia are occasionally associated with SGBS17. 
Cardiac anomalies 
 
Congenital heart defects in SGBS have been well described in a number of studies. A 
cardiac defect can be found in up to 36% of patients with SGBS19. The majority are structural 
cardiac malformations, but cardiomyopathies and isolated ECG abnormalities are also 
described. There is uncertainty as to whether or not the ECG abnormalities reflect a true 
association with SGBS or just selection bias19. The structural cardiac anomalies are mostly 
atrioseptal and ventriculoseptal defects or simple valve defects 19. 
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Neurological abnormalities 
 
The neurological features in SGBS vary widely but hypotonia is the most consistent 
neurological finding in SGBS6. Functional and cognitive outcomes can be normal in some 
boys, whereas developmental delay occurs in others. Speech delay is present in 50%, and 
motor delay in 34% of affected individuals. Severe intellectual disability is rare20.  
Seizures and EEG abnormalities have been described7,8. Structural central nervous system 
abnormalities include Dandy-Walker malformations and agenesis of the corpus callosum8,9. 
Other manifestations 
 
The fingernails can be broad and dysplastic 19. 
2.3.3 Neoplasia 
 
SGBS belongs to the group of overgrowth syndromes in which a common factor is the risk of 
development of a tumour10. In particular in SGBS there is a clearly defined increased risk in 
developing embryonic cancers7,18 especially of the kidney and liver9. Wilms tumour, 
neuroblastoma, hepatocellular carcinoma, hepatoblastoma and testicular gonadoblastoma 
are the tumours that have been documented. Although it is widely acknowledged in the 
literature that risk for malignancy is sufficiently increased to warrant tumour surveillance8,13 , 
only a few studies quote risk figures. These range from 5% to15%9,14,20.   
2.3.4 Population specific phenotype 
 
Most reports in the literature do not state the population or ethnic group of the affected 
individuals. The studies that did mention the ethnic background of their patients revealed 
considerable diversity, ranging from the original report by Golabi concerning a Puerto-Rican 
boy, to reports from Europe (Germany, Italy, Holland), Australia, Angola, the Caribbean, 
Jordan and Japan 6,9,10,11,12,14. The phenotype in these studies was comparable leading to the 
reasonable assumption that there is no significant difference in clinical presentation between 
different population groups. 
During the literature search no reports of SGBS in the South African population could be 
found. 
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2.3.5 Genetic basis and inheritance 
Introduction and inheritance 
 
In the original reports describing SGBS it was already recognised that there was an X-linked 
recessive mode of inheritance. Affected individuals were male, and females showed no or 
only mild features of SGBS 5,6. This inheritance pattern is often useful in distinguishing 
SGBS from the other overgrowth syndromes.  
The main indicator of recurrence risk would be the carrier status of the mother of the affected 
boy. If she is a carrier of the determinant gene, the recurrence risk would be 50% for any 
further male offspring. If she is not a carrier the recurrence risk would be very low. The 
authors Hughes-Benzie et al, in 1996, suggested that it may be that new mutations are 
responsible for the majority of males with SGBS21. In contrast to this, these authors then go 
on to recommend that for counselling purposes it may be empirically assumed that one in 
three affected boys are due to a new mutation, meaning that two in three mothers will be 
carriers of the mutation. The authors felt that more research is needed to confirm this21. A 
molecular diagnosis greatly improves the accuracy of recurrence risk. 
Genetic background 
 
Two genes have been implicated in SGBS. In 1994 the region was mapped to Xq25-2722. In 
1996 the first gene involved in SGBS - glypican 3 (GPC3) - was identified by investigating 
the breakpoints on the X-chromosomes of two affected females with X-autosome 
translocations23.  
Adjacent to GPC3 is glypican 4 (GPC4); previous reports have shown that deletions in 
GPC3 can extend to GPC4 2. Recently, an isolated GPC4 duplication has been implicated 
as a second locus for SGBS 24.  
GPC3 
 
The gene GPC3 at Xq26 contains eight exons, and is 500 kilobases long. It belongs to the 
glypicans family; which are heparan sulfate proteoglycans that attach to the cell surface by 
glycosylphosphatidylinositol anchors16 where they are involved in the signalling of 
morphogens and heparan-binding growth factors. Glypicans are expressed in mesodermal 
tissues, such as the kidneys, liver and lungs 9. GPC3 can also interact with insulin-like 
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growth factor 2 (IGF2), which is involved in another overgrowth syndrome, Beckwith-
Wiedemann Syndrome.  
The mutation spectrum within GPC3 causing SGBS is broad, ranging from deletions to point 
mutations. The original report describing GPC3 mutations was that of three different 
deletions7, and in further studies additional deletions were identified. Deletions can involve 
one or more exons, or may be a microdeletion within an exon2,11. In 50% of persons with a 
deletion, this involves exon eight and extends to the centromere2. Large deletions are found 
in up to 20% of persons with SGBS 25. 
With advances in molecular technology, it has been possible to further investigate GPC3.  
Direct sequencing has identified numerous different point mutations, while intronic mutations 
affecting the splice site have also been reported9. Point mutations are most frequently found 
in exon 3, which is the largest exon encompassing 40% of the gene. There is no evidence 
for hot spots for mutations2. 
The deletions and point mutations which have been documented to date all introduce 
premature stop codons resulting in an unstable protein2.This truncated protein has reduced 
adherence to the cell surface. It is suggested that deletions and point mutations are equally 
common in SGBS9 and that the majority are unique.  
Not all individuals with SGBS have been found to have a mutation in GPC3. The question 
therefore remains as to what the cause for SGBS in these affected persons is. The 
possibilities include other mechanisms of gene silencing, the involvement of promotor areas, 
or that there are more genes involved13. Different studies have reported mutation detection 
rates varying from 37%20 to 70% 2,19.  
GPC4  
 
The gene GPC4 is located next to the 3‟ end of GPC3 on the X-chromosome. GPC4 is also 
a part of the heparan sulfate proteoglycans family and is also bound to the cell surface by 
glycosylphosphatidylinositol. 
Deletions encompassing both GPC3 and GPC4 have previously been reported in SGBS. No 
deletions involving GPC4 alone have been found in males with SGBS, and neither have 
point mutations in the GPC4 gene2.  
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A recent study revealed a duplication of exon 1 to 9 of GPC4 in a male with SGBS24. In this 
family it was confirmed as disease-causing when it was shown to segregate with other 
clinically affected males. This is the first time that an isolated GPC4 mutation has been 
identified in a family with SGBS. The exact pathogenic mechanism of GPC4 duplications 
requires further investigation24.  
In previous investigations GPC4 polymorphisms had been identified, but found not to cause 
loss of function and therefore assumed not to be disease-causing in SGBS2. 
Genotype – phenotype correlation 
 
SGBS is likely the result of a loss of function mechanisms2,20,21. Thus far there has been no 
correlation between the genotype and the phenotype. The size of the deletion is also not 
related to the severity of the clinical features 17. The phenotype is highly variable even within 
families where affected males share the same molecular mutation2. 
2.3.6 Testing strategy and methods 
 
The information in this review seems to indicate that it is necessary to investigate GPC3 for 
both deletions and point mutations. A testing strategy has been suggested in GeneReviews3, 
starting with sequence analysis of GPC3, followed by deletion/duplication analysis of GPC3. 
If no mutation is found, deletion and duplication testing of GPC4 should be undertaken. 
Investigations undertaken just after the identification of the gene involved in SGBS relied on 
polymerase chain reaction (PCR) amplification of exons 1 to 8, and Southern blotting to 
identify deletions21. Both DNA extracted from lymphocytes and fibroblasts have been used. 
The primers commonly employed in earlier studies are those defined by Pilia et al in 199623, 
and Huber et al in 199726, although lately most investigators have added either intronic 
primers, or redefined primers2,11,12. Newly designed primers covering all eight exons, and 
including intronic-exonic borders are now in use. These primers also include an internal 
primer set in exon 3 to better cover this large exon25. After amplification the products are 
evaluated by electrophoresis on various gels2. Thereafter, sequencing of the amplified 
products in forward and reverse directions is conducted and these results analysed using 
different software programs10. Mutations are confirmed by repeating PCR amplification and 
sequencing2   
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2.4 CONCLUSION 
 
This literature review confirms that there have been many reports documenting the clinical 
phenotype of SGBS and that many of the manifestations are relatively nonspecific and can 
be found in various other syndromes. The combination of macrosomia, characteristic facial 
features and multiple congenital abnormalities is suggestive of SGBS.  A comprehensive 
review of the literature concerning the clinical phenotype of SGBS supported the diagnosis 
of SGBS in the boys in the existing study. 
No data from South Africa regarding SGBS could be identified in this literature search. 
Although no apparent phenotypic differences between population groups are described, the 
importance of documenting the phenotype of South African patients would be to raise 
awareness of the diagnosis and to improve clinical diagnostic skills in this country.  
The genetic basis of SGBS has only been elucidated in the past two decades and 
determinant mutations are not identifiable in all persons with SGBS. The deletions and point 
mutations identified to date have all been unique and there is still a need for further 
investigation into the mutation spectrum. This literature review confirms that there is a good 
chance of finding a mutation in GPC3 in persons with SGBS. There has been only one 
reported case of a GPC4 duplication causing SGBS and currently no other genes are known 
to be implicated in the condition.  
The practical implication of this investigation will be that if a mutation in GPC3 is identified in 
the two probands, the clinical diagnosis of SGBS will be confirmed. It would then be possible 
to proceed to offer testing to at risk family members to establish their individual risk. 
Establishing the methodology for GPC3 sequencing would facilitate future establishment of 
diagnostic testing facilities for SGBS in South Africa. 
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3.1 Study rationale 
 
Simpson-Golabi-Behmel syndrome (SGBS) is an X-linked overgrowth syndrome. It is 
characterised by macrosomia, distinctive facial features, and multiple congenital 
abnormalities. 
Two genes have been found to be associated with SGBS. They are glypican 3 (GPC3) and 
glypican 4 (GPC4).  Mutations in GPC3 are detected in 37-70% of affected males.  
The aim of this research was to describe the phenotype of two unrelated boys and to attempt 
to make a molecular diagnosis in their families by investigating GPC3. 
3.2 Methods 
 
This study is a case series with a clinical and molecular component. Two male probands 
were identified, proband B and S. Their clinical records were reviewed to obtain relevant 
history and their physical manifestations were documented.  
DNA was extracted from proband B and S as well as their mothers. All eight exons of GPC3 
were amplified by polymerase chain reaction (PCR). The products were first analysed for 
large gene deletions and thereafter sequencing analysis was undertaken to identify point 
mutations.  
3.3 Results 
 
The clinical phenotype of proband B and S was documented and found to be consistent with 
that reported in the literature.  
DNA analysis of proband B revealed a mutation in exon 4 of GPC3. This mutation consisted 
of a deletion of four nucleotides, TAGA, at nucleotide position 1071, and an insertion of three 
nucleotides, CTT. This mutation can be labelled as p.358Arg-PheFSX373 (NM_004484.3).  
No deletion or mutation in GPC3 was identified in proband S. 
3.4 Discussion 
 
The boys who were included in this investigation exhibited many of the more common 
features seen in SGBS. 
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Both probands B and S had characteristic facial features and showed varying degrees of 
pre- and postnatal macrosomia.  
These two boys also exhibited skeletal and cardiovascular abnormalities that have been 
described in SGBS. Proband B had hypospadias which can occur in SGBS. Proband S had 
visceromegaly which can also be a feature of SGBS. Proband B developed a Wilms tumour, 
which is a cancer that is associated with SGBS in the literature.  
The main clinical manifestations which prompted a diagnosis of SGBS in the two boys were 
macrosomia, coarse facial features, macroglossia and a grooved tongue. 
The molecular analysis of proband B‟s DNA revealed a frameshift mutation resulting in a 
premature stop codon. This stop codon occurs in exon 4 meaning that the majority of the 
protein is not translated. This is a previously undescribed mutation. 
3.5 Conclusion 
 
This report represents the first published description of South African patients with SGBS. 
The phenotype of the boys included in this research is similar to that previously reported in 
the literature. On this basis clinicians in South Africa can be guided by the literature in the 
diagnosis of SGBS. 
The importance of regular tumour surveillance is reinforced in this research by virtue of the 
Wilms tumour that proband B developed.  
The mutation found in proband B represents a novel, and likely disease-causing mutation. 
The literature supports this statement as the functional effect of this mutation, a premature 
stop codon, has been described numerous times. 
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4.1 INTRODUCTION 
 
Phenotype 
 
Simpson-Golabi-Behmel syndrome (SGBS)[OMIM #312870] is an X-linked overgrowth 
syndrome. It is characterised by macrosomia, distinctive facial features, and multiple 
congenital abnormalities1.The condition was originally reported by Simpson et al2 and similar 
features were described in males seen by Golabi and Rosen3, and by Behmel et al4. In 1988 
Neri coined the term “Simpson-Golabi-Behmel syndrome” after recognising that the previous 
authors had been describing the same syndrome5.  
It is widely accepted that SGBS is under-diagnosed, probably because it is a relatively newly 
described syndrome and there is clinical overlap with the other overgrowth syndromes6.  
The SGBS is typically characterised by pre- and postnatal overgrowth, although not all 
affected persons have postnatal overgrowth7. In a newborn with macrosomia this diagnosis 
warrants consideration if there are the typical facies or renal or skeletal abnormalities8.In the 
majority of cases prenatal overgrowth, coarse facies, supernumerary nipples, and hand 
anomalies are present7.  
The typical facial features include a coarse appearance, hypertelorism, and downslanting 
palpebral fissures. The nose is often upturned, and macrostomia and macroglossia are 
usual. Grooves in the tongue and lower lip are also common findings.  
The hands are broad and short, and poly- or syndactyly can occur. Other skeletal 
manifestations include scoliosis, vertebral abnormalities, and pectus deformities.  
Genito-urinary abnormalities in SGBS are usually mild and include cryptorchidism and 
inguinal hernias, but more serious abnormalities such as penoscrotal hypospadias and 
ambiguous genitalia have been described9.  
Abdominal anomalies which can occur include intestinal malformations and umbilical or 
diaphragmatic hernias.  
Renal involvement is not uncommon. The kidneys are hydronephrotic in 15% of affected 
individuals and may be polycystic or enlarged. Nephromegaly or renal dysplasia occurs in 
31% of persons with SGBS7. 
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Cardiac abnormalities are present in up to 36% of patients with SGBS. The majority of these 
are structural defects. Cardiomyopathies and electrocardiogram (ECG) abnormalities also 
occur10. 
Structural neurological abnormalities have been described, such as Dandy Walker 
malformations and corpus callosum anomalies. Hypotonia is frequent6.The developmental 
outcome is variable, ranging from normality or mild learning difficulties, to infrequently severe 
intellectual dysfunction. Speech delay has been documented in 50% of boys with SGBS, and 
motor delays in 34%7.  
The SGBS is associated with an increased risk of developing embryonal tumours. 
Carcinoma has been described in 10 affected children, and in every instance the tumour was 
intra-abdominal11. The tumour spectrum included four Wilms tumours, three 
hepatoblastomas, one adrenal neuroblastoma, one gonadoblastoma and one hepatocellular 
carcinoma. An elevated risk of developing a tumour has been well documented and it is 
generally accepted that the risk is high enough to warrant tumour surveillance protocols to 
be put in place. Lapuzina et al (2005) have quoted this risk to be up to 10%11. 
Genotype 
 
Two genes have been found to be associated with SGBS. They are glypican 3 (GPC3) and 
glypican 4 (GPC4).  GPC3 was the first gene identified. This discovery was made while 
investigating affected females with X-autosome translocations12. The gene is located at 
Xq26, and encodes a heparan sulfate proteoglycan which is involved with growth factor 
signalling and morphogenesis. GPC3 is expressed in tissues of the mesoderm, notably the 
kidneys, liver and lungs13. GPC3 interacts with insulin-like growth factor type 2 (IGF2) and 
can alter its signalling activities14. It has been postulated that GPC3 and IGF2 form a 
complex, and that GPC3 could be involved in downregulating IGF2 via the IGF2 receptor. 
This has however not been confirmed in subsequent studies7.The mutation spectrum is 
broad, but most cases of SGBS are due to either deletions or point mutations14.  There are 
no known hot spots, and mutations can occur throughout the gene15. All of these mutations 
have a loss of function effect, and there is no genotype-phenotype correlation7. Mutations 
have been reported to be detectable in 37-70% of patients1.  
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GPC4 is adjacent to the 3' end of GPC3. Previously deletions involving GPC3 have been 
reported to extend to GPC4 as well. GPC4 mutations alone have not been associated with 
SGBS until recently when a duplication of exons one to nine of GPC4 was found to be 
disease-causing in a family with SGBS16.  
SGBS is inherited in an X-linked recessive manner. Carrier females are usually unaffected 
but may exhibit some minor clinical features, such as tall stature1 with a short broad nose 
and a wide mouth4. 
Research aims 
 
The aim of this research was to describe the phenotype of two unrelated boys and to attempt 
to make a molecular diagnosis in their families by investigating GPC3. It is hoped that this 
project will improve clinical diagnostic ability by delineating the phenotype encountered in 
our South African patients. Furthermore, it will also be investigated whether there are any 
significant differences between published literature and the affected boys investigated. 
Identifying the disease-causing mutation would not only confirm a clinical diagnosis, but is 
also necessary to give an accurate recurrence risk to the parents. If a disease-causing 
mutation is found it would be possible to make diagnostic testing available to other at risk 
family members.  Currently, molecular analysis of GPC3 is not readily available to patients in 
the public health arena in South Africa.   
4.2 METHODS 
 
The type of study undertaken was a case-series with a clinical and molecular component. 
For the sake of expediency the two boys who participated in the study were named proband 
B and proband S, belonging to family B and S respectively. B and S represents the first letter 
of each individual proband‟s first name. 
4.2.1 Patient selection 
 
Proband B was ascertained after referral to the Division of Human Genetics of the University 
of Cape Town. Proband S had been attending the Genetic Clinic at Red Cross War 
Memorial Children‟s Hospital for several years. In both these boys a clinical diagnosis of 
SGBS was made in the genetic clinic after careful review of the clinical features and the 
literature. These individuals were seen between January 2011 and May 2012. They were the 
only patients in whom a diagnosis of SGBS was considered likely during this period. 
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The inclusion criteria were  
 Boys clinically affected with SGBS 
 Availability for clinical examination 
 Mothers of affected boys who were available for examination 
4.2.2 Ethical approval 
 
Ethical approval was sought and granted from the Human Research Ethics committee, 
Faculty of Health Sciences of the University of Cape Town. (appendix 9) The eldest of the 
two probands was five years of age and the other was aged four years. Both mothers gave 
written consent for themselves, and their children to participate in the research. Assent from 
an affected child is only required after the arbitrary age of seven years. Both probands are 
under this age and were not considered emotionally mature enough to be able to understand 
the pertinent information. 
4.2.3 Phenotypic documentation 
 
Hospital records were reviewed to obtain a family history, clinical information, and results of 
special investigations. Clinical consultations were arranged with both mothers and their 
sons. A detailed clinical examination was performed on both mothers and their sons by the 
investigator. A clinical information sheet was designed to facilitate directed questions 
regarding demographic data, antenatal, birthing, postnatal and developmental history. The 
documentation of phenotypic features was aided by a tick sheet designed to incorporate the 
typical features of SGBS as described in the literature. The sheet included a space to 
elaborate if a clinical feature did not appear on the tick sheet. Provision was also made for 
recording investigations which had been undertaken for tumour surveillance. (appendices 1 
and 2) 
4.2.4 Molecular analysis 
 
The molecular analysis was undertaken by the investigator in the Ramesar Laboratory, 
Division of Human Genetics, University of Cape Town (UCT).  
A flow diagram was designed to aid in the molecular diagnostic investigations. The testing 
strategy used is similar to those previously described in the literature17. This approach was 
also the most cost-effective way to proceed with testing. The flow diagram can also assist in 
determining the course of action, once a mutation has been identified (appendices 3 and 4). 
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4.2.4.1 GPC3 polymerase chain reaction (PCR) assay design and optimisation 
 
The primers selected for the amplification of GPC3 coding regions were those reported on in 
2007 by Sakazume et al (Table 4.1)17. These primer pairs were investigated for their 
suitability by evaluating their amplification specificity and also their tendency for secondary 
structure formation. Initially, the primer sequences were submitted to Primer-BLAST18 to 
determine that they were indeed specific to the area of interest. Secondly, they were 
analysed using OligoAnalyzer 3.119 to assess their stability. Exon 3 was analysed with two 
overlapping sets of primers due to the large size of the coding region. These primer sets 
were termed 3A and 3B. 
 
Table 4.1: Primers used for the amplification of GPC3 coding regions (Sakazume et al 
[2007])17 
Gene region Primer sequence (5’ – 3’) Size of product (bp) 
GPC3exon1 F CTCAGGGTACAGCCACCAC 399 
GPC3exon1 R CAGGTAGCTGCGAGGAAACT  
GPC3exon2 F GCCCAAATAATGATGCCACT 277 
GPC3exon2 R GGTGTGGGTGTGTGAGAGAG  
 GPC3exon3a F TACCTGCTACTGGCCACCTC 493 
GPC3exon3a R GAGCAAGACGTGACCTGAAA  
 GPC3exon3b F CGGCCACAGTCCTTACTGA 501 
GPC3exon3b R TTTTCACACTGGATTTTCATGC  
GPC3exon4 F TTTCACTCTAGTGGTTTTTGACCTT 302 
GPC3exon4 R TGGGGGAAGAAATTGAAGTG  
GPC3exon5 F TTTCTGGTGCAATTAATGGAGA 267 
GPC3exon5 R TTGCCTCTTATGCACAGATGTT  
GPC3exon6 F CTCTCTCTCTCCCCCTCCTC 255 
GPC3exon6 R GCTTTTCCTTTGTTTGGGACT  
GPC3exon7 F TTGTGTGTTGCAGGGAATGT 327 
GPC3exon7 R TGCAGACCCACCTGAGAAAT  
GPC3exon8 F GCTCGAGCTGTGCATAGTGT 306 
GPC3exon8 R CCCTTTATCGAGGAAGACCAC  
Key: bp – base pair(s) 
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DNA was extracted by the Division Human Genetics, UCT for proband S and his mother, 
whilst the National Health Laboratory Services (NHLS), Groote Schuur Hospital (GSH), 
extracted DNA for proband B and his mother.  The extraction method employed by the 
NHLS involved the QIAamp DNA blood mini kit (Whitehead scientific, Brackenfell, South 
Africa). In the Division Human Genetics, DNA was extracted from peripheral blood 
lymphocytes using the salting-out method described by Miller et al20. 
The DNA was then assessed for its quantity and quality by spectrophotometry (NanoDrop® 
ND-1000, Thermo Fisher Scientific, Wilmington, Delaware, USA) and electrophoresis on a 
1.5% (w/v) agarose (Lonza, Basel, Switzerland) gel.  
The PCR assay was optimised using DNA obtained from a healthy research participant. 
During this process the optimal temperature was investigated on a Bio-Rad T100™ gradient 
thermal cycler (Bio-Rad, Hercules, California, USA), and titrations were performed for 
Magnesium Chloride (MgCl2) and pH to enhance primer annealing and the amplification 
yield of products (Table 4.2). 
 
             Table 4.2: Assay optimisation 
GPC3 region Temperature MgCl2 and pH titration 
Exon 1    62.7°C 1.5mM MgCl2  and pH 8.5 
Exon 2 59°C 1.5mM MgCl2  and pH 8.5 
Exon 3 59°C 1.5mM MgCl2  and pH 8.5 
  Exon 3A 59°C 1.5mM MgCl2  and pH 8.5 
  Exon 3B 59°C 1.5mM MgCl2  and pH 8.5 
Exon 4 59°C 1.5mM MgCl2  and pH 8.5 
Exon 5 59°C 1.5mM MgCl2  and pH 8.5 
Exon 6 59°C          1.5Mm MgCl2 and pH8.6            
         (Buffer no 6 of PCR    
         optimisation kit, Roche) 
Exon 7 59°C 1.5mM MgCl2  and pH 8.5 
Exon 8 59°C 1.5mM MgCl2  and pH 8.5 
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4.2.4.2 Amplification of GPC3 
Standard conditions for PCR amplification: 
 
The DNA of both participants was amplified in a final PCR volume of 25ɥl. For all the GPC3 
exon regions, except for exon 6, this reaction consisted of 100ng of genomic DNA, 1x 
GoTaq® (Promega, Madison, Wi, USA) reaction buffer, 200ɥM of deoxyribonucleotide 
triphosphates (dNTP) (Bioline, London, UK), 0.4ɥM of each primer (sense and antisense) 
and 0.5 units of GoTaq® DNA Polymerase (Promega). For GPC3 exon 6 amplification, the 
PCR Optimization Kit Buffer number 6 (Roche, Basel, Switzerland) was used.  
The PCR reactions were performed on the T100TM thermal cycler (Bio-Rad Laboratories). It 
consisted of an initial DNA denaturation step (95°C for 5 minutes), followed by amplification 
over 35 cycles. Each amplification cycle consisted of 30 seconds of denaturation at 95°C, 30 
seconds of primer-template annealing (at the optimal temperatures in table 4.2), 40 seconds 
of product extension at 72°C. Finally, a cycle of 7 minutes at 72°C allowed for the extended 
synthesis of incomplete DNA fragments. 
The yield and specificity of the aforementioned reaction were investigated by loading 5µl of 
the PCR amplification product on a 1.5% (w/v) agarose gel (Lonza) and electrophoresing 
this at 160V for 40 minutes. To assist with visualisation, ethidium bromide (0.5µg/ml, Sigma-
Aldrich, St Louis, Missouri, USA) was added and the gel was photographed under UV 
illumination (Uvipro Gold, Uvitec, Cambridge, UK). The PCR products were visible and could 
be sized by comparison to the size ladder GeneRulerTM 100bp DNA ladder Plus (Fermentas, 
Hanover, Maryland, USA). The fragments were scrutinised to assess the amount of PCR 
product obtained and also whether it corresponded with the expected reference sequence 
size.   
Direct cycle sequencing of GPC3 genomic regions 
 
In order to obtain the best possible sequencing result, excess single stranded primers and 
dNTPs were removed from the amplified PCR products. An amount of 5µl of PCR product 
was combined with 0.2µl Exonuclease I (20 U/µl; Fermentas), 0.5µL FastAp (1 U/µl; 
Fermentas) and 4.3µl of distilled water and incubated on the GeneAmp 9700 PCR system 
(Applied Biosystems, Carlsbad, California, USA) at 37°C for one hour. The reaction ended 
with enzymatic inactivation at 72°C for 15 minutes.   
- 41 - 
 
Direct sequencing of the amplified GPC3 exonic regions of both probands was undertaken.  
In direct cycle sequencing, primer sequences employed during amplification of DNA target 
template are used in conjunction with dNTPs and dideoxynucleotides (ddNTPs). The 
template is elongated by the addition of dNTPs and this elongation continues until a ddNTP 
is incorporated. The process is then promptly terminated as ddNTPs lack a 3‟ hydroxyl group 
for another dNTP to adhere to. During an automated sequencing process each ddNTP is 
differentially displayed due to its specific fluorophore label.  
The sequencing reaction had a final reaction volume of 10µl. It consisted of 2µl of BigDye® 
Terminator v3.1 Cycle Sequencing mix (Applied Biosystems), 2µl of dilution buffer (Applied 
Biosystems) and 0.5ɥl of either a sense or antisense primer (at a final concentration of 
0.4ɥM). Depending on the initial amplification yield, the amount of PCR product ranged from 
3 - 5.5µl. The reaction was performed on the Bio-Rad T100™ thermal cycler (Bio-Rad) with 
initial denaturation of PCR products at 98°C for 5 min, followed by 35 cycles consisting of 
96°C for 15 seconds, 55°C for 10 seconds and 60°C for 4 minutes. 
To remove the unincorporated ddNTPs from the newly synthesised DNA fragments, 2.5ɥl of 
sodium acetate (pH5.2, 2.5M) and 30µl of absolute alcohol was added to the sequencing 
reaction mix. This was incubated overnight at -20 °C. Following the incubation reaction the 
sample was centrifuged for 10 minutes at 9300 rpm and the supernatant discarded. After the 
addition of 30µl of 70% ethanol, the sample was centrifuged for 10 minutes at 9300 rpm. 
Once the supernatant had been removed, the sample was air-dried. Sequencing for both 
probands and their respective mothers was performed on the ABI PRISM 3130xl Genetic 
Analyser (Applied Biosystem, HITACHI, Santa Clara, California, USA). The results of the 
sequencing reaction were analysed using SEQMAN (DNASTAR®, SeqManTM) software 
systems. The mutation found was investigated using two databases, the London Open 
Variation Database21 and the NCBI website22.  
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4.3 RESULTS 
4.3.1 Phenotypic description of families B and S 
4.3.1.1 Proband B 
 
Proband B was evaluated by the investigator at the age of five years and nine months. He 
had previously been seen by the Division of Human Genetics of the University of Cape Town 
on two occasions - at birth, and at four years of age.  
Family history 
 
There was no family history of any intellectual concerns.  There was a maternal cousin who 
had a cardiac lesion and bowel problems, but no further details were known. The boy is his 
mother‟s only child. 
 
Figure 4.1: Pedigree of proband B’s family. 
 
Perinatal history 
 
No exposure to known teratogens was reported during the pregnancy. No antenatal 
investigations were undertaken. The only complication during pregnancy was that of 
unexplained premature rupture of membranes at seven months.  
Proband B was born by vaginal delivery in the breech position. His Apgar scores were 
recorded as 7 and 9. According to his mother he was born at seven months gestation. There 
SGBS 
Cardiac lesion and bowel abnormalities 
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are no records documenting the gestation in weeks, which could have been anywhere from 
28 to 32 weeks. His birth weight was 2.1kg. Consideration of the two extremes in gestational 
age in weeks would place him in a range from the 90th to above the 90th centile. His head 
circumference was 31cm, which is anywhere from above the 50th to above the 90th centile in 
this context. His length at birth was not documented. 
He was admitted to neonatal ICU after birth and only discharged home after six weeks. He 
required ventilation for an aspiration pneumonia and also had prolonged jaundice. Notably 
he also had a single episode of hypoglycaemia after birth. 
Clinical features 
 
a) Growth parameters: 
    
 
Figure 4.2: Growth parameters proband B. The weight, height and head circumference of 
proband B illustrating generalised overgrowth 
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b) Facial features 
 
The boy had a long face, with hypertelorism, epicanthic folds and an upturned nose. His 
nasal bridge was broad. His mouth tended to be open and he had macrostomia and 
macroglossia with a grooved tongue and prognathism. His ears were normal.   
 
                                         
 
Figure 4.3: A photograph of proband B.  Hypertelorism, a broad nasal bridge and 
epicanthic folds are demonstrated. Macrostomia, macroglossia and a grooved tongue are 
evident in this image. 
 
c) Skeletal system        
                                                                                                                                                                                                                                                                                                                                                  
Proband B had pectus excavatum and a marked lordosis. No obvious scoliosis was noted.  
There was no polydactyly or any other obvious hand abnormalities. He did not have a cleft 
lip or palate. On chest X-ray there were 13 ribs noted on each side.  
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Figure 4.4: A full length image of proband B. Proband B had a marked pectus   
excavatum and a protruding abdomen.  
 
d) Cardiovascular system  
 
He had a soft ejection systolic murmur with no signs of cardiac failure. Cardiovascular 
investigations revealed an atrioseptal defect (ASD) and valvular pulmonary stenosis. 
e) Genito-urinary system  
 
He had had bilateral inguinal hernias repaired. No other hernias were documented. He had 
hypospadias and a shawl scrotum.  
f) Abdominal system 
 
Abdominal examination revealed a large mass in the left flank which raised suspicion of 
neoplasia. No other organomegaly or mass was detected. Although he had received 
treatment for constipation on several occasions, there had not been any concern of intestinal 
malformations noted in his medical records.   
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g) Neurological involvement 
 
Formal central nervous system imaging had not been undertaken. His developmental 
milestones had all been within the normal range but he had been noted to be hypotonic. At 
five years his speech is still slightly difficult to comprehend although his vocabulary was 
good. The rest of his development was appropriate for his age. 
There were no focal neurological abnormalities.   
h) Tumours 
 
He was diagnosed with a Wilms tumour of his left kidney at the age of five years and nine 
months.  
Clinical course and management: 
 
At two months of age proband B had an apnoeic attack and was admitted to the neonatal 
ICU.  
It was during this time that ambiguous genitalia were noted. A diagnosis of a hypospadias 
with a penoscrotal meatus and chordee was made. He was treated as an undervirilised 
male, with possible partial androgen insensitivity syndrome.   
At three months of age the boy had a bilateral inguinal hernia repair and a right orchidopexy.  
He had a first stage hypospadias repair at almost five years of age. A year later he was 
investigated for a mass in his left flank. A Wilms tumour was diagnosed. He was started on 
chemotherapy and the tumour responded well. After chemotherapy he had a partial left 
nephrectomy. His latest imaging revealed no residual tumour or recurrence.      
During investigations for the tumour he was also found to have right hydronephrosis 
secondary to a pelvo-ureteric obstruction. The obstruction was relieved by inserting a stent. 
Although the kidney remained hydronephrotic, renal function has shown great improvement. 
The obstruction is still present despite a pyeloplasty.  
He is still under the care of oncologists and urologists undergoing standard tumour 
surveillance1 (Table 4.3) and is awaiting final repair of his hypospadias. His cardiac lesion 
does not need intervention. 
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Table 4.3: Recommended tumour surveillance program1 
 Physical 
examination 
Abdominal 
ultrasound 
Alpha feto 
protein and 
ßHCG 
Urinary 
catecholamines, 
VMA and HVA 
Chest Xray 
0-4 
years 
3 monthly 3-4 monthly 4 monthly 4 monthly Annually 
4-7 
years 
4 monthly 3-4 monthly 6 monthly 6 monthly Annually 
>7 years Biannually Yearly Annually Annually Annually 
  
Investigations 
 
Following the early diagnosis of ambiguous genitalia proband B had extensive endocrine 
investigations: 
 A karyotype revealed a normal male pattern. 46,XY. 
 Oestradiol, Follicular stimulating hormone (FSH) and Luteinising hormone (LH) levels 
were normal 
 Dehydroepiandosterone (DHEAS) and 17-hydroxyprogesterone (17-OHP) were 
mildly raised but not considered to be a concern. 
 Adequate testosterone response with ßHCG stimulation test.  
 Pelvic ultrasound revealed no Mullerian structures and two testes were seen. 
 5 α-reductase deficiency was excluded. 
Cardiology: 
 Atrioseptal defect with valvular pulmonary stenosis 
Investigations of Wilms tumour 
 Histology obtained from a fine-needle aspiration confirmed a nephroblastoma.  
 An MRI of his chest showed metastatic spread to the left lung base. 
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Description of mother of proband B 
 
Proband B‟s mother was a healthy woman. She had jaundice as a child but no other 
neonatal concerns. She was diagnosed with scoliosis which resolved spontaneously during 
her teens. She was tall, and at 1.81 cm plotted above the 97th centile.  She had a long face 
with no other obvious dysmorphic features. She did not have any learning difficulties.   
 
                                          
 
Figure 4.5: Proband B and his mother. Proband B‟s mother had tall stature and a long 
face.       
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4.3.1.2 Proband S 
 
Proband S was evaluated at four years and two months of age. He had been followed up for 
a prolonged period at the genetic clinic at Red Cross War Memorial Children‟s Hospital.  
Family history 
 
There was a family history of mild intellectual disability, which is indicated in the pedigree. 
There was no family history of congenital malformations 
 
 
                
 
Figure 4.6: Pedigree of proband S’s family. There is a family history of intellectual 
disability 
 
Perinatal history  
 
His mother has asthma, but was otherwise in good health during the pregnancy. There was 
no history of teratogen exposure. Ultrasound investigations during the mother‟s pregnancy 
did not reveal any abnormalities.  
SGBS 
Intellectual disability 
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Proband S was born via normal vertex delivery at term. He had Apgar scores of 8 and 9. His 
birth weight was 3.2 kg (10th centile). The birth head circumference was 33cm (5th centile).  
After birth he was admitted to the neonatal ICU following an apnoeic episode and he 
received assisted ventilation for two weeks. This illness was presumed to be due to 
unconfirmed sepsis and he also had jaundice which necessitated phototherapy. There were 
no hypoglycaemic events. 
Clinical features 
a) Growth parameters 
 
                      
Figure 4.7: Growth parameters of proband S. Head circumference is well above the 95th 
centile 
 
b) Facial features 
 
The boy had a coarse face with hypertelorism, downslanted palpebral fissures, epicanthic 
folds and an upturned nose. His tongue was protruding, macroglossic, and had a central 
groove. He also had macrostomia. He was mildly hirsute with a low posterior hair line. His 
ears were normal.   
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Figure 4.8:  A profile photograph of proband S. There is hirsutism of his forehead                                                                                                                                                                                                                                
 
                                                   
 
Figure 4.9:  A photograph of proband S. The features evident in this photograph are a 
coarse face, hypertelorism, epicanthic folds and an upturned nose. There is also 
macroglossia with a grooved tongue 
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c) Skeletal 
 
Proband S had broad, short fingers with bilateral fifth finger clinodactyly. His toes were broad 
and he had pes planus. He also had a mild lordosis causing his stomach to appear to be 
protruding. There was no evidence of a cleft lip or palate.  
d) Cardiology  
 
The boy had a patent ductus arteriosus with a patent foramen ovale.This was evaluated by 
cardiologist and found to have closed spontaneously.  
e) Genito-urinary system 
 
His genitalia were normal. 
f) Abdominal system 
 
He had hepatomegaly of 2cm below the costal margin. This feature had been stable for a 
number of years. 
g) Neurological abnormalities 
 
He was hypotonic, with no focal neurological deficit.  He had been assessed by a 
developmental specialist and was found to have a developmental quotient of 60, in keeping 
with mild intellectual disability.  
h) Tumours 
 
At the time of this research he had not developed any tumours.                                                
Clinical course and management 
 
During the neonatal period proband S had very loose skin and a diagnosis of cutis laxa was 
considered and later abandoned.  
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From six months onward his head circumference showed a steady centile increase when 
compared to his other growth parameters. A metabolic work-up was undertaken during this 
time and no abnormalities were detected.  
He is currently undergoing tumour surveillance according to the recommended protocol 
(Table 4.3). 
He is attending a special educational needs school. 
Investigations  
 
A Karyotype revealed a normal male pattern. 46,XY.  
Thyroid function was normal 
A metabolic work-up included the following tests 
 Plasma and urine amino-acid profiles were normal 
 Urine organic acid profile was normal 
 No urine reducing substances 
An investigation into storage disorders was also undertaken: 
 Urinary glycosaminoglycans was normal 
 Leucocyte vacuolation was normal 
 Normal alpha glucosidase 
 
A skin biopsy in the neonatal period evaluating elastin and collagen showed non-specific 
changes 
A chest X-ray revealed 11 ribs on the right and 12 on the left. 
On ultrasound of his abdomen, the boy had homogeneous mild hepatomegaly with no other 
abnormality. His kidneys were reported as normal. 
An MRI of his brain at two years of age showed atrophy and a peritrigonal high signal which 
were suggestive of a hypoxic insult at birth. No other specific abnormalities were found. 
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Description of mother of proband S 
 
Proband S‟s mother had a mild intellectual disability and attended a school for learners with 
special educational needs. She was functionally independent and employed. Her height was 
176cm which is above the 97th centile. She had a long face, with a high arched palate. The 
other family members with intellectual disability were not available for examination. 
4.3.1.3 Comparison of clinical features  
 
There are no diagnostic criteria available to assist in the clinical diagnosis of SGBS. There 
are however, some clinical features that would be suggestive of a diagnosis of SGBS if they 
are present1. Table 4.4 and 4.5 compare proband B and S to common features and 
malformations which have been documented in SGBS.   
 
Table 4.4: Comparison of the facial features of probands B and S to common features 
documented in SGBS 
Craniofacial features1 Proband B Proband S 
Macrocephaly Yes Yes 
Hypertelorism, epicanthic folds, downslanted 
palpebral fissures 
Yes Yes 
Redundant skin over glabella No No 
Macrostomia Yes Yes 
Macroglossia Yes Yes 
Midline groove lower lip or tongue Yes Yes 
Cleft lip or palate or high, narrow palate No No 
Macrognathia Yes No 
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Table 4.5: Comparison of the associated features in probands B and S compared with those 
frequently described in SGBS 
Associated features1 Proband B Proband S 
Macrosomia Yes No 
Congenital heart disease Yes Yes 
Conduction defects No No 
Supernumerary nipples No No 
Diastasis recti/umbilical hernia No No 
Diaphragmatic hernia No No 
Renal dysplasia/nephromegaly Yes No 
Cryptorchidism/hypospadias Yes No 
Hand anomalies No Yes 
Rib abnormalities Yes Yes 
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4.3.2 Molecular analysis of families B and S 
 
The molecular results of both probands B and S are presented together under this heading. 
This format is used for the sake of expediency in the light of the negative findings in proband 
S.   
4.3.2.1 DNA extraction 
 
The spectrophotometry of the DNA obtained from all samples revealed results that were 
suitable for analysis. The extracted DNA also showed a good yield on gel electrophoresis 
(Lonza). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: An image of a 1.5% agarose gel for the assessment of genomic DNA 
integrity.   Lanes 1 and 4 contain 500ng of Generuler 100bp Plus (Fermentas), lanes 2 and 
3 contain 200ng of Proband B and his mother‟s extracted genomic DNA, respectively.   
 
 
 
 
 
 
1000 bp 
500 bp 
High molecular 
weight genomic 
DNA 
1     2      3      4 
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4.3.2.2 PCR amplification 
 
In order to assess whether all the GPC3 exon regions amplified during the PCR reaction the 
products were scrutinised for specificity and amplification yield for downstream applications 
by electrophoresis of 5µl of the product on a 1.5% agarose gel. All the fragments in both 
probands, as well as their mothers, were successfully amplified and were visible on the 
agarose gel. This not only indicated that the PCR amplification process was successful but 
also that there were no deletions present resulting in altered banding patterns between the 
probands and their mothers. Figure 4.11 illustrates the results of the four participants.  
4.3.2.3 Sequencing reaction 
Proband B: 
 
The entire coding region, including intron-exon boundaries of GPC3, was analysed by direct 
DNA sequencing.  
A mutation was found in exon 4 of proband B. This mutation consists of a deletion of four 
nucleotides, TAGA, at nucleotide position 1071, and an insertion of three nucleotides, CTT. 
This mutation is designated c.1071delTAGAinsCTT. This alteration causes a frameshift, 
which results in a premature stop codon. Figure 4.12 illustrates this mutation. 
At a protein level this tetranucleotide deletion results in a disruption of the amino acid 
reading frame which causes Arginine to be replaced by Phenylalanine at position 358, with a 
resulting premature stop codon at position 373. Using Genbank accession no. NM_004484.3 
as a reference, the mutation can be described as p.358Arg-PheFSX373. As this premature 
stop codon occurs in exon 4, the majority of the coding sequence of GPC3 is not translated.  
This mutation was confirmed to be present in proband B‟s mother in the heterozygous state. 
Proband S: 
 
Sequencing results of all exons of GPC3 were analysed and no variation when compared to 
the reference sequence, was found in either probands S or his mother.  
- 58 - 
 
                  
                                   
Figure 4.11: An image depicting the agarose gel electrophoreses of amplified PCR 
products for all four participants. M contains the 500ng of GeneRuler 100bp Plus 
(Fermentas)                                                                                                                         
Exon 2, 1=proband B, 2=proband B‟s mother, 3=proband S, 4=proband S‟s mother, 5=no-
template control. Expected size=277 bp                                                                                     
Exon 3A, 6=proband B, 7=proband B‟s mother, 8=proband S, 9=proband S‟s mother, 10=no-
template control. Expected size=493 bp                                                                             
Exon 3B, 11=proband B, 12= proband B‟s mother, 13=proband S, 14=proband S‟s mother, 
15=no-template control. Expected size=501 bp                                                                  
Exon 4, 16=proband B, 17= proband B‟s mother, 18=proband S, 19=proband S‟s mother, 
20=no-template control. Expected size=302 bp                                                                     
Exon 5, 21=proband B, 22= proband B‟s mother, 23=proband S, 24=proband S‟s mother, 
25=no-template control. Expected size=267 bp                                                                             
Exon 7, 26=proband B, 27= proband B‟s mother, 28=proband S, 29=proband S‟s mother, 
30=no-template control. Exoected size=327 bp                                                                  
Exon 8, 31=proband B, 32 = proband B‟s mother, 33=proband S, 34=proband S‟s mother, 
35=no-template control. Expected size=306 bp                                                                  
Exon 6, 36=proband B, 37 = proband B‟s mother, 38=proband S, 39=proband S‟s mother, 
40=no-template control. Expected size=255 bp                                                                  
Exon 1, 41=proband B, 42 = proband B‟s mother, 43=proband S, 44=proband S‟s mother, 
45=no-template control. Expected size=399 bp                                                                     
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Figure 4.12: An electropherogram of proband B and his mother illustrating the mutation detected in exon 4 of the GPC3 gene. The 
sequencing reaction was analysed using DNASTAR SeqMan. Label 1 is the reference sequence. Label 2 and 3 is the sequencing result of 
exon 4 of proband S‟s mother revealing no mutations. Label 5 and 6 is the normal sequencing result of exon 4 in proband S. Label 4 and 7 
indicate the sequencing result of exon 4 in proband B, the arrow indicates the beginning of the TCTA deletion, and insertion of AAG (the 
annotation used in the text is that of the complementary strand, i.e. deletion TAGA and insertion of CTT). Label 8 is the results of proband B‟s 
mother, her results reveal the same mutation as her son, in a heterozygous state
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4.4  DISCUSSION 
4.4.1 Phenotype 
 
There are no published data describing SGBS in South Africa. The boys who were included 
in this investigation exhibited many of the more common features described in SGBS. A 
limitation of this study is that both of the probands investigated were of Caucasian ancestry. 
This is not representative of the diverse populations groups in South Africa, however there is 
no indication in the literature reviewed for this research that differences in presentation 
would be expected3,13. More information regarding phenotypes in other ethnic groups in 
South Africa would have been valuable. 
There are ultrasound abnormalities that can lead to consideration of an antenatal diagnosis 
of SGBS. These are macrosomia, an increased nuchal translucency, congenital 
diaphragmatic hernia, visceromegaly, and renal abnormalities. Polyhydramnios and an 
elevated maternal serum alpha fetoprotein (msAFP) in addition to the above anomalies 
warrant consideration of SGBS as a diagnosis23. In South Africa there is limited access to 
detailed fetal anomaly scans and this information will be useful mainly in tertiary centres 
were this service is available. The msAFP investigation is offered routinely in the private 
sector in South Africa and although an elevation in this value is seen in pregnancies affected 
with SGBS, an increased msAFP may indicate of many other conditions, including neural 
tube defects24. 
Antenatal ultrasound investigations were only undertaken in proband S. These findings were 
normal. An antenatal diagnosis of SGBS was not considered in either of our probands. Both 
probands‟ mothers will, however, be offered detailed fetal ultrasound monitoring during 
future pregnancies. 
Proband B had been macrosomic since birth. Proband S had a weight above the 75th centile, 
and a head circumference above the 97th centile. His height was around the 50th centile. 
Although not strictly fulfilling the definition of macrosomia, he showed an element of 
postnatal overgrowth by acceleration of his growth parameters and evolution of head 
circumference.   
Both probands had facial features consistent with those described in the literature. They both 
had hypertelorism, an upturned nose and macrostomia. These features are often described 
in individuals affected with SGBS6. Both boys also had macroglossia with a midline groove in 
the tongue. Macroglossia is seen in 40% of individuals with SGBS7. In addition proband B 
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had a prominent jaw and a broad nasal root which is also frequently described6. Proband S 
has a coarse face, and is also hirsute. Hirsutism is not typically a feature of SGBS, but a 
coarse facies has been reported in 83% of persons with SGBS7. Both proband B and S had 
epicanthic folds, which is a classical, although non-specific characteristic of SGBS25.  
Some of the typical skeletal features previously described were also seen in the boys 
included in this research. Both had numerical rib abnormalities and lordosis. Proband B had 
pectus excavatum, and proband S had short broad hands – both are frequent skeletal 
manifestations of SGBS6. Notably neither polydactyly nor palatal clefting were present in 
these individuals.  
The boys both had structural cardiac lesions which did not require any surgical intervention. 
These structural malformations, an atrioseptal defect (ASD) and a patent ductus arteriosus 
(PDA), have previously been described in SGBS10. 
Hydronephrosis and inguinal hernias are commonly described in the SGBS, while 
hypospadias has less frequently been documented9. The severity of the genito-urinary 
abnormalities documented in proband B has been reported in other individuals with SGBS9. 
Visceromegaly is reported as a common feature and this would be in keeping with the non-
progressive hepatomegaly in proband S6. Proband S did not have ear lobe creases, an 
abdominal wall defect or other clinical features to suggest Beckwith Wiedeman. His facial 
features were also not in keeping with the bossed forehead or prominent chin described in 
Sotos syndrome. 
The variability in intellectual outcome is also evident in these boys, with one showing mild 
intellectual disability and the other appearing to develop normally. Proband S has a family 
history of mild intellectual disability. His mother and his maternal aunt are similarly affected 
and his maternal grandfather and great-aunt were reported to have intellectual difficulties 
too. There are two possible explanations for this.  
Firstly, the familial intellectual disability can be explained by SGBS. This feature has been 
described in many males with SGBS. With respect to the affected females, their intellectual 
disability could be explained by SGBS carrier status. There have been reports of female 
carriers of SGBS exhibiting mild manifestations of the condition. A female with an X-
autosome translocation causing skewed X-inactivation has previously been shown to have 
typical features of SGBS. Furthermore there has been a report of a girl with developmental 
delay and dysmorphic features strongly suggestive of SGBS. She was heterozygous for a 
mutation in GPC3. Two of her brothers clinically affected with SGBS had a similar mutation. 
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X-inactivation studies revealed a pattern of inactivation moderately skewed toward her 
normal X-chromosome (71-80% inactivation of her normal allele). Her mother was of normal 
intelligence and had only mild clinical signs of SGBS. Her mother‟s inactivation studies 
showed much lower levels of inactivation of her unaffected allele. This led the authors to 
postulate that skewed X-inactivation was the cause of her phenotype and that there appears 
to be a minimal threshold value of X-inactivation at which clinical features will be 
manifested26. It is thus plausible that proband S‟s mother could have skewed X-inactivation 
surpassing this threshold causing her to have intellectual disability, tall stature and mild facial 
dysmorphic features. All the females with intellectual difficulties are connected to proband S 
via an X-linked inheritance pattern and therefore the same could be true for them. In the 
case of proband S‟s maternal grandfather, there is a possibility that he could have had 
SGBS himself, causing both his daughters to be obligate carriers of the condition. Studies for 
skewing of X-inactivation were beyond the scope of this research but could have provided 
useful information.  
Secondly, the cause of the intellectual disability in either proband S, or any of his similarly 
affected family members, may be multifactorial or related to other genetic factors. Although 
the inheritance pattern in this family is compatible with X-linked inheritance it is not the only 
method of inheritance plausible. Unfortunately the boy‟s aunt was not available for 
examination, and his maternal grandfather has passed away so it was not possible to further 
investigate the cause of their intellectual disability.  
Proband S had a normal karyotype. A karyotype was not performed on his mother.  
Proband B developed a Wilms tumour. This tumour has been described in at least four other 
affected individuals and the association between Wilms tumours and SGBS is well 
established. Overall, the literature reports 10 instances in which persons with SGBS 
developed a tumour11, the proband in this research represents an 11th case. The affected 
boy has recovered well and he will continue to receive tumour surveillance in his hometown.  
Both boys included in this study had some typical and associated features of SGBS. Their 
manifestations are consistent with those described in the literature. The diagnosis is not 
easy to make and there is considerable overlap with the other syndromes. Equally, the facial 
features may not be recognisable in smaller babies. Both probands were diagnosed in early 
childhood. The main clinical manifestations which prompted this diagnosis in the two boys 
were macrosomia, coarse facial features, macroglossia and a grooved tongue.  
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4.4.2  Molecular analysis 
 
Many different mutations in GPC3 have been described as causative in the SGBS. No 
hotspots for these mutations have been identified but frameshift mutations and deletions 
have been reported on numerous occasions6,14,17. All mutations associated with SGBS either 
remove a start codon or introduce a premature stop codon. These premature stop codons 
invariably lead to a truncated protein with insufficient cysteine residues in the conserved 
cysteine motif. This motif is thought to be important for the tertiary structure of glypicans15. 
These abnormal proteins will also not contain the site for heparan sulfate attachment, 
causing failure of heparan sulfate substitution. 
Although the specific mutation found in proband B has not previously been reported, its 
effects appear to be similar to other mutations associated with SGBS. The sequence 
anomaly disrupts the reading frame and introduces a premature stop codon, resulting in the 
majority of the protein not being translated.  
Two databases were investigated to evaluate whether the mutation in Proband B has been 
previously reported to be associated with SGBS. The Leiden Open Variation database21 did 
not contain any mutations in GPC3 and although the NCBI website22 had many known 
mutations the above mutation has not been previously reported. This indicates that this is a 
novel mutation.  
Proband B‟s mother was found to be heterozygous for this mutation. Accurate counselling 
regarding the recurrence risk for futures pregnancies is now possible. In any future 
pregnancy, a male fetus will have a 50% chance of being affected with SGBS. A female 
fetus will have a 50% chance of being a carrier of this mutation. 
The research results were delivered to proband B‟s mother during a genetic counselling 
session. Antenatal diagnosis will be available to her should she want to pursue this option, 
following confirmation of this mutation in a diagnostic laboratory. This testing could be 
carried out as a prenatal diagnosis through a chorionic villous biopsy or amniocentesis. 
Preimplantation genetic diagnosis could also be used to prevent another affected pregnancy, 
this is however an expensive procedure and is not routinely available to patients using 
government facilities.   
If the decision is made not to undergo any prenatal testing and a pregnancy is conceived 
naturally, testing of a male infant could be offered to the mother. Testing of a minor would be 
ethically justified in this case as the result would have a direct impact on his medical 
management. Should this potential sibling be affected with SGBS, early initiation of a tumour 
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surveillance program may be considered. The manifestations of SGBS can be subtle, 
especially in infants, and a clinical diagnosis may only be evident at a later stage. This could 
lead to a delay in monitoring for tumour development. Cascade screening following a genetic 
counselling process has also been offered to this family.  
No mutation was identified in proband S even though mutations in GPC3 are present in up to 
70% of individuals with SGBS1. There are several possible reasons for this. The first 
possibility is that in proband S, SGBS is caused by a mutation in a gene other than GPC3. 
The likely other candidate gene is GPC4, although there has been only one report of a 
duplication in GPC4 without mutations in GPC316. No other candidate genes have been 
reported but a number of clinically affected boys have not yet had the molecular basis of 
their SGBS identified, raising the possibility of additional genes being implicated.   
A second possible reason that a mutation was not found could be because it is in the intronic 
region of GPC3. The primers used in this study were designed to encompass intron exon 
boundaries and also a significant part of the introns. This makes it less likely that there is a 
mutation in the introns that will affect the splice site and cause a disruption in the protein.  
Finally it is possible that proband S does not have SGBS.  SGBS is a difficult clinical 
diagnosis to make as it has significant phenotypic overlap with other overgrowth syndromes. 
As the clinical phenotype described in proband S is consistent with previous reports of 
SGBS, this is a less likely scenario. For this reason he will still continue with his tumour 
surveillance program.  
4.5 CONCLUSION 
 
This report represents the first published description of South African patients with SGBS. 
This condition is a recently described, under-diagnosed syndrome. The implications of a 
diagnosis of SGBS do not only relate to the clinical diagnosis and recurrence risk in siblings, 
but also to the predisposition for developing tumours.  
In this research, clinical features in two probands from two unrelated families were 
documented. The phenotype of the boys included in this research is similar to that previously 
reported in the literature. On this basis clinicians in South Africa can be guided by the 
literature in the diagnosis of SGBS. There are no diagnostic criteria but in this report an 
attempt was made to highlight the more common clinical findings. Macrosomia and typical 
facial features associated with other malformations in the skeletal, cardiovascular, renal or 
uro-genital systems are useful clinical indicators. Consistent manifestations amongst the two 
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probands in this study were their facial features and the element of overgrowth. The 
associated abnormalities and malformations were varied, although both had cardiac 
involvement. The importance of regular tumour surveillance is reinforced in this research by 
the documentation of the Wilms tumour that proband B developed.  
An X-linked inheritance pattern can be used to distinguish SGBS from the other overgrowth 
syndromes as this condition is the only overgrowth syndrome known to exhibit this form of 
genetic transmission. The pedigree in family S could be consistent with X-linked inheritance.   
The mutation found in proband B represents a novel, and likely disease-causing mutation. 
The literature supports this statement as the functional effect of this mutation, a premature 
stop codon, has been described numerous times. Identification of the mutation in this family 
presents the possibility of antenatal testing for the mother in future pregnancies, as well as 
testing of other at risk relatives in this family if diagnostically confirmed.  
No mutation was identified in proband S. The possible reasons for this are discussed under 
the previous heading. Further investigation of GPC4 and also dosage analysis of GPC3 
could help to make a diagnosis and will be considered in the future. 
Routine molecular testing for SGBS is currently unavailable in South Africa. It is hoped 
however, that this research will benefit other children in South Africa as testing can now be 
offered on a research basis. If there is a demand for testing it could also be converted into a 
diagnostic test using the methods and analysis optimised in this project. Testing for X-linked 
conditions such as SGBS is important as it offers the possibility of carrier testing which could 
have implications for extended family members. SGBS is also associated with a risk of 
developing embryonal tumours, confirmation or exclusion of a clinical diagnosis would then 
also indicate whether an individual needs to continue with further tumour surveillance or not.  
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5.1 A ppendix 1 
Name: 
 
 
 
 
Date of birth and folder 
number: 
 
Pedigree: 
 
 
Sex: Age: 
Antenatal history:  
 
 
 
Antenatal ultrasounds:  
 
 
Delivery: 
 
 
Where: Gestation: Method: Apgars 
Postnatal complications:  
 
 
 
 
Birth parameters: Weight (kg): COH (cm): Length (cm): 
Post natal parameters 
 
 
Weight (kg): COH (cm): Height (cm): 
Facial features: Coarse facies                                         Other      explain: 
Hypertelorism  
Downslanted palpebral fissures   
Upturned nose  
Macrostomia  
Macroglossia 
Grooved tongue  
High arched palate  
Cleft lip/palate  
Prominent jaw  
Thorax: 
 
 
Pectus deformities  
Supernumerary nipples   
Other      explain:  
 
Cardiovascular system: 
 
 
Cardiac murmur  
Echography report  explain: 
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Abdominal: 
 
 
Umbilical hernia  
Diaphragmatic hernia  
Gastrointestinal obstructions  
Organomegaly  
Masses felt       explain: 
 
Limbs: 
 
 
Hand polydactyly                           Toe syndactyly  
Hand syndactyly                                      Broad toes  
Blunt finger tips                                      Clinodactyly  
Hypoplastic /dysplastic nails                Other     explain: 
Broad, short fingers   
Genitourinary 
abnormalities: 
 
 
 
 
Skeletal abnormalities: 
 
 
 
CNS abnormalities: 
 
 
 
Development milestones: 
 
 
Smile: Sat: Walk: Talk: 
Development (months):  
 
Gross motor: 
 
 
Fine motor: Social: Speech: 
Investigations done: Genetic tests: Other: 
Tumour surveillance Ultrasounds done: 
 
 
AFP done: 
Tumours found (age):  
 
 
- 72 - 
 
5.2 Appendix 2 
Additional description for information needed on datasheet for clinical examination: 
1. Name: Name of patient 
2. Date of birth and folder number: Date of birth and folder number. 
3. Pedigree: Refer to family‟s pedigree and enter pedigree number 
4. Sex: Male or female 
5. Age: For adults in years, for children in months 
6. Antenatal history: Document any problems during the pregnancy. Specifically relating 
to the following: 
 Use of teratogens 
 Diabetes 
 Medications used 
7. Antenatal ultrasound: Document at which gestational age and short report on what 
was seen. If known, comment specifically on poly/oligohydramnios 
8. Delivery: State clearly at which hospital and the type of delivery 
9. Postnatal complications: Noting any prolonged neonatal stay, ventilation, or problems 
maintaining glucose. 
10. Birth parameters: As recorded on Road to Health card 
11. Post natal parameters: Documented the current/last measurements taken.  
12. Facial features: Refer to tick sheet 
13. Thorax: Refer to tick sheet 
14. Cardiovascular system: Refer to tick sheet 
15. Abdominal: Refer to tick sheet 
16. Limbs: Refer to tick sheet  
17. Genitourinary system: note any abnormality and relevant times of surgery and follow 
up. Also comment on renal ultrasounds that were done 
18. Skeletal abnormalities: Comment on radiological abnormalities. If bone age was done 
please note. Comment on scoliosis. 
19. Central nervous system: Document if any imaging done and what was found. Careful 
documentation of neurological exam, especially regarding tone. Ask regarding 
seizures. 
20. Developmental milestones: Record in months/weeks 
21. Development: rough estimation using guidelines  
22. Investigations done: please note when done 
23. Tumour surveillance: Note intervals of surveillance  
24. Tumours found: Note carefully the findings, management and outcome 
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5.3 Appendix 3 
Flow diagram for molecular investigation 
 
 
 
 
 
  
Extract DNA proband B 
and S 
PCR amplification of eight        
exons 
    Whole exon deletion detected? 
yes no 
Confirm deletion by 
comparing to reference 
sample and literature 
Sequencing of all amplified exons 
yes 
no 
PCR amplification of deleted 
exon in proband’s mother 
Deletion found  
yes no 
Testing of other at risk 
family members 
Likely low recurrence 
risk 
Mutation found 
yes 
no 
GPC3 exonic sequencing 
abnormalities and exon 
deletions as cause for SGBS 
excluded 
Refer to flow diagram 2  
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5.4  Appendix 4 
Flow diagram for molecular investigation 
 
Confirmation of mutation by 
comparing to reference sample and 
literature? 
yes no 
Sequence the relevant area in 
the proband’s mother 
Mutation found? 
no 
Likely low recurrence risk 
yes 
Testing of other at 
risk family 
members 
Mutation potentially affecting GPC3 
function? 
Mutation found? 
yes no 
Sequence the relevant 
area in the proband’s 
mother 
 
yes no 
Likely low 
recurrence risk 
Testing of other at risk family 
members 
 
Inconclusive results 
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5.5 Appendix 5:  English version 
UNIVERSITY OF CAPE TOWN 
 DIVISION OF HUMAN GENETICS 
INFORMED CONSENT FOR RESEARCH PROJECT: 
A clinical and molecular investigation of Simpson-Golabi-Behmel syndrome 
 
I, …………………………………………………………………………………………….., hereby 
voluntarily consent to  my child ……………………………………………….. / my genetic  
material being investigated for a disease causing mutation in the potential genes causing 
Simpson-Golabi-Behmel syndrome(SGBS) in my family.  
INFORMATION REGARDING RESEARCH STUDY: 
The aims of this study are: 
1. To clinically describe family members with, or at risk of being carriers of SGBS 
2. To look for a disease causing mutation in potential genes implicated in SGBS 
3. If a mutation is found in an affected person, to look for the disease causing mutation 
in at risk family members  
Each participant may have: 
1. A clinical examination done by one of the medical doctors at the Division of Human 
Genetics 
2. A blood / saliva sample taken to extract DNA  
Initially only DNA of affected persons will be analysed for mutations in genes implicated in 
SGBS, if any are found the at risk family member‟s DNA will be tested for the same 
mutation.  
By consenting for this study you are also consenting for your DNA to be stored for future 
use. Any further genetic investigations will relate only to SGBS. 
All results will be delivered to the relevant persons at the end of the study period where 
possible. Implications of these results will also be discussed in detail as part of the genetic 
counselling process.  
By consenting to this research study permission is also granted for publishing of the data.  
No identifiable data will be used in publication. 
Photos may be published with your consent. 
Participation in this study is voluntary and may be withdrawn at any stage, without 
any penalty to future care. 
Signature: ………………………………          Date: ……………………………………………. 
Witness signature: ……………………           Date: ……………………………………………. 
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5.6 Appendix 5: Afrikaanse weergawe 
UNVERSITEIT VAN KAAPSTAD 
 AFDELING VAN MENSLIKE GENETIKA 
INGELIGTE TOESTEMMING VIR NAVORSINGSPROJEK: 
‘n Kliniese en molekulêre ondersoek van Simpson-Golabi-Behmel sindroom 
Ek ………………………………………………………………………………………………, gee 
hiermee vrywillig toestemming dat my kind ………………………………………………… /my 
genetiese materiaal ondersoek mag word vir „n mutasie in die moontlike gene wat Simpson-
Golabi-behmel sindroom (SGBS) in my familie veroorsaak. 
INLIGTING AANGAANDE DIE NAVORSINGSPROJEK: 
Die doelwitte van hierdie navorsingsprojek is as volg: 
1. Om die kliniese beeld van familielede met SGBS, asook die wat „n risiko loop om 
draers van SGBS te wees, te beskryf. 
2. Om in die gene wat moontlik SGBS veroorsaak te soek vir „n mutasie wat 
verantwoordelik is vir SGBS. 
3. Indien „n mutasie wat SGBS veroorsaak gevind word in „n geaffekteerde persoon, om 
in hoë risiko familielede na die mutasie te soek. 
Elke deelnemer aan die studie kan die volgende verwag: 
1. „n Kliniese ondersoek deur een van die dokters by die Afdeling van Menslike 
Genetika  
2. „n Bloed / spoeg monster om DNA van te isoleer. 
Aanvanklik sal net die DNA van geaffekteerde seuns ondersoek word vir mutasies in die 
gene wat SGBS kan veroorsaak.  
Indien „n mutasie gevind word sal hoë risiko familielede se DNA ondersoek word. 
Deur u toestemming tot deelname aan die studie te gee, gee u ook toestemming dat u DNA 
gestoor mag word vir toekomstige gebruik. Enige verdere genetiese toetsing sal net oor 
SGBS handel. 
Alle uitslae sal aan die einde van die studie aan die relevante persone bekend gemaak 
word, waar moontlik. Gevolge van hierdie uitslae sal in detail bespreek word tydens „n 
genetiese beradingsessie.  
Toestemming tot deelname in die studie sluit ook toestemming tot publikasie in. 
Geen identifiseerbare data sal gebruik word nie. 
Foto‟s mag gepubliseer word met u toestemming. 
Deelname aan hierdie studie is vrywillig, en ontrekking kan op enige stadium geskied. 
Indien u ontrek sal daar geen negatiewe uitwerking op u behandeling of sorg wees 
nie.  
Handtekening: ………………………………      Datum: ……………………………… 
Getuie handtekening ………………… …..       Datum: ………………………………. 
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5.7 Appendix 6 : English Version 
INFORMATION SHEET FOR PARTICIPANTS OF RESEARCH STUDY: 
 
A clinical and molecular investigation of Simpson-Golabi-Behmel syndrome 
 
1. You have been approached to participate in this study because of your or your 
family‟s history of Simpson-Golabi-Behmel syndrome (SGBS).  
2. People with SGBS are often big babies when they are born; they also tend to be 
taller adults than others. People with SGBS also share similar facial features. Some 
people with SGBS have other problems too, such as with their hearts, backs, or 
kidneys. People with SGBS may also have difficulties with learning. The other 
important thing is that people with SGBS could have some growths in their kidneys 
and livers, and they need regular monitoring for these. 
SGBS is an X-linked disorder; this means that usually it is boys who are affected with 
it, although sometimes girls could also have a few signs of it. Usually however, 
women are only “carriers” of the genetic change causing SGBS. If a woman is a 
carrier of this change, she probably has no problems herself, but will have a 50% 
chance of passing it on to her son – causing him to have SGBS.  
3. This study will look for a change the GPC3 gene in boys with SGBS. 
4. If a change is found, further investigation into at risk family members will be done. If 
no change is found, family members‟ blood will not be investigated for the change.  
5. As part of this research, a clinical examination may be done on participants by one of 
the doctors working in the Division of Human Genetics of the University of Cape 
Town. Secondly a sample of blood/saliva may also be taken to isolate your genetic 
material. 
6. The risk to you during the peripheral blood taking is the same as with routine blood 
taking. Should we gather a saliva sample from you there will be no physical risk 
involved.  
7. Your genetic material will be stored safely, and will not be used for any other 
purposes, other than SGBS.  
8. All the information gathered during this study will be safely stored in locked offices or 
in password protected computers. 
9. When this information is published it will be done without any identifiable data.  
10. Photographs may be published with your consent, but the eyes will be covered. 
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11. If your genetic material was analysed for the change seen in SGBS the result will be 
given to you in person (where possible), and explained in detail. All effort will be 
made to contact you. Please also inform us if your contact details change during the 
study period. 
12. If at any time during the study you wish to withdraw your consent you may do so. 
There will be no penalties to your future care if you decide to withdraw from the 
study. 
13.  Please feel free to contact the following people if you have any problems or 
questions about the research: 
Dr Careni Pretorius  
Tel: 021 406 6698 
E-mail: ce.pretorius@uct.ac.za 
Dr Karen Fieggen 
Tel: 021 406 6298 
E-mail: karen.fieggen@uct.ac.za 
Sr Legg/ Sr Sklar  
Tel: 021 406 6304 
14. If you have any questions regarding your rights as participants in this research 
project please contact Prof M. Blockman, Chair of the Research Ethics Committee of 
the University of Cape Town on 021 406 6496.  
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5.8 Appendix 6 : Afrikaanse weergawe 
INLIGTINGSTUK VIR DEELNEMERS AAN NAVORSINGSPROJEK: 
 
‘n Kliniese en Molekulêre ondersoek van Simpson-Golabi-Behmel sindroom 
 
1. U is genader om aan die navorsingsprojek deel te neem as gevolg van u of u familie 
se geskiedenis van Simpson-Golabi-Behmel sindroom (SGBS). 
2. Mense met SGBS is gewoonlik groot babas met geboorte, hulle is ook meesal langer 
as ander volwassenes. Somige mense met SGBS het ander probleme ook, soos met 
hulle hart, niere, of ruê. Mense met SGBS het ook soms leerprobleme. Die ander 
belangrike ding is dat mense met SGBS  groeisels in hulle lewers en niere kan kry, 
daarom benodig hulle gereelde ondersoek daarvoor. 
SGBS is „n X-gekoppelde sindroom, dit beteken dat seuns meesal geaffekteer word, 
terwyl vroue net “draers” is van die genetiese verandering. Somtyds kan vroue egter 
„n paar tekens van SGBS hê. Indien „n vrou „n draer is van die genetiese 
verandering, het sy „n 50% kans om dit aan haar seun oor te dra – hy sal dan SGBS 
hê. 
3. Hierdie navorsingsprojek gaan vir „n verandering in die GPC3 geen soek in seuns 
met SGBS. Veranderinge in die geen SGBS kan veroorsaak.  
4.  Indien „n verandering wat ons dink verantwoordelik is vir SGBS gevind word in „n 
seun met SGBS, sal ons verdere ondersoek instel na verdere familielede. Indien ons 
geen verandering vind in „n seun met SGBS, sal ons nie verder na ander familielede 
se genetiese materiaal kyk nie.  
5. As deel van hierdie navorsing mag deelnemers „n kliniese ondersoek deur een van 
die dokters van die Afdeling van Menslike Genetika ondergaan. Verder mag daar ook 
„n bloed of spoeg monster geneem word om genetiese materiaal te kry.  
6. Die risiko‟s verbonde aan die bloed monster is dieselfde as met „n roetine 
bloedtrekking.  Indien u „n spoeg monster verskaf is daar geen fisiese risiko tot u nie.  
7. U genetiese materiaal sal veilig gestoor word, dit sal nie vir ander doeleindes buiten 
SGBS  gebruik word nie. 
8. Al die inligting wat tydens die navorsing ingewin word sal in „n geslote kantoor, of in 
„n rekenaar met „n sleutelwoord gestoor word.  
9. Wanneer die navorsing gepubliseer word, sal dit gedoen word sonder 
identifiseerbare inligting 
10. Foto‟s mag gepubliseer word met u toestemming, mits die oë weggesteek word. 
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11. Indien u genetiese materiaal  geanaliseer is vir die verandering in SGBS, sal die 
uitslag persoonlik (waar moontlik) vir u gegee word. Dit sal ook in meer detail 
bespreek word. Alle voorsiening sal gemaak word om u in die hande te kry, maar 
indien moontlik lig ons asseblief in indien u kontakinligiting verander. 
12. Indien u op enige stadium tydens die navorsing u toestemming wil ontrek mag u so 
doen. Daar sal geen negatiewe uitwerking op u behandeling of sorg wees nie.  
13. Kontak enige van die volgende mense gerus indien u enige probleme met of vrae oor 
die navorsing het: 
Dr Careni Pretorius 
Tel: 021 406 6698 
E-pos: ce.pretorius@uct.ac.za 
Dr Karen Fieggen 
Tel: 021 406 6298 
E-mail: karen.fieggen@uct.ac.za 
Sr Legg/Sr Sklar 
Tel: 021 406 6304 
14. As enige vrae oor „n regte as deelnemer  aan hierdie navorsingsprojek het, kontak 
gerus Prof M Blockman, die Voorsitter van die Etiese Hersiening Komitee van die 
Universiteit van Kaapstad by 021 406 6496. 
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5.9 Appendix 7: English Version 
UNIVERSITY OF CAPE TOWN 
DIVISION OF HUMAN GENETICS 
ASSENT FOR RESEARCH PROJECT: 
 
A clinical and molecular investigation of Simpson-Golabi-Behmel syndrome 
1. This study is being done by the doctors at the University of Cape Town to try and 
learn more about a genetic condition called Simpson-Golabi-Behmel syndrome 
(SGBS) 
2. You and some members of your family have been asked to participate in the study 
because SGBS is in your family. 
3. The doctors are trying to see if they can learn more about how someone with SGBS 
looks, and how it happens. This is so they can better help your and other people‟s 
families in the future.  
4. If you decide to be a part of the study one of the doctors from Genetics will examine 
you, and also collect some saliva (spit) from you. The way they collect the saliva is by 
asking you to spit into a container. 
5. Nothing that will be done will be painful, or harmful to you. 
6. Everything that is done during the study will be confidential, meaning that no one who 
is not a part of the study will know what you did. 
7. You can decide for yourself whether you want to be a part of this study. If you decide 
to not be a part of it then it no one will be angry with you, and you will still get all the 
help and care that you need.  
 
Signature: ……………………………………         Date: …………………………………………..  
 
Witness signature: ………………………….         Date: ……………………………………………           
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5.10 Appendix 7: Afrikaanse weergawe 
 
UNVERSITEIT VAN KAAPSTAD 
AFDELING VAN MENSLIKE GENETIKA 
INSTEMMINGSVORM VIR NAVORSINGSPROJEK 
‘n Kliniese en molekulêre ondersoek van Simpson-Golabi-Behmel sindroom 
 
1. Die dokters by die Universiteit van Kaapstad is besig om „n studie te doen oor „n 
genetiese toestand wat mens Simpson-Golabi-Behmel sindroom (SGBS) noem. 
2. Jy en van jou famlielede is uitgenooi om aan die studie deel te neem omdat SGBS in 
jou familie is. 
3. Die dokters doen hierdie studie om te sien of hulle meer kan leer van hoe iemand 
met SGBS lyk, en ook hoe dit gebeur.  Dit is sodat hulle jou, en ander families met 
SGBS in die toekoms nog beter kan help 
4. As jy besluit om aan die studie deel te neem, sal een van die dokters van Genetika 
jou ondersoek, en ook „n spoeg monster neem van jou. Hulle sal hierdie spoeg 
versamel deur vir jou te vra om in „n buisie te spoeg. 
5. Niks wat in die studie gedoen word sal seer wees, of jou in gevaar stel nie.  
6. Alles wat tydens die studie gedoen word sal geheim gehou word, en niemand wat nie 
„n deel was van die studie sal weet wat jy gedoen het nie. 
7. Jy mag self besluit of jy will deel wees van hierdie studie. As jy besluit om nie deel te 
neem nie sal niemand vir jou kwaad wees nie, en jy sal nogsteeds al die sorg kry wat 
jy nodig het.  
  
Handtekening: ………………………………....…      Datum: …………………………………… 
 
Getuie handtekening ………………………...…..     Datum: ……………………………………. 
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5.11 Appendix 8 
 
Funding for MMED investigating 2 patients with Simpson-Golabi-Behmel syndrome 
 
Introduction: 
Simpson-Golabi-Behmel syndrome (SGBS) is an X-linked skeletal overgrowth disorder. Its 
incidence is not known but is believed to be under diagnosed.  The disorder is characterised 
by macrosomia, distinctive facial features and multiple congenital abnormalities. The birth 
weight or length is usually above the 95th centile, reflecting prenatal onset of overgrowth. 
Distinctive facial features include macrocephaly, hypertelorism, epicanthic folds and 
downslanting palpebral fissures. The facies is coarse, with a broad nasal bridge and 
anteverted nares. Macrostomia and macroglossia with a grooved tongue are also present. 
Congenital abnormalities can include a cleft palate, congenital heart lesions, conduction 
defects, supernumery nipples and umbilical hernia. Renal and genital abnormalities have 
been reported, as have skeletal abnormalities leading to lumbar lordosis.  Although normal 
development can occur, a spectrum of intellectual disability ranging from mild to severe is 
common. Importantly, in SGBS there is about a 10% chance of developing a malignant 
tumour. The 5 tumour types described in SGBS are Wilms tumour, hepatoblastoma, adrenal 
neuroblastoma, gonadoblastoma and hepatocellular blastoma. Heterozygous females can 
have some mild manifestation of SGBS due to skewed X-inactivation. 
Mutations in two genes have been associated with SGBS - GPC3 and GPC 4. These genes 
are adjacent to each other at the Xq26 locus.  Sequence analysis of GPC3 can identify up to 
70% of clinically affected males. GPC3 consists of 8 exons and span 500kb. Numerous 
different mutations have been reported in all 8 exons of GPC3. 50% of GPC3 mutations are 
deletions in exon 8.  GPC4 comprises 9 exons, but testing of this gene is only currently 
available on a research basis. It is uncertain how abnormalities in these genes cause SGBS, 
it is however known that the normal gene product of GPC3 is involved in cell growth and 
division. 
 
Aim of this MMED research project: 
Two patients with a clinical diagnosis of SGBS have been seen by the Division of Human 
Genetics at the University of Cape Town. DNA is available from both these boys, as well as 
their mothers. The aim of this MMED project is twofold. The first aim is to delineate the 
history, clinical phenotype and general manifestations of these two patients. The second aim 
is to sequence the GPC3 gene in an attempt to find a disease causing mutation. As far as 
known, testing of GPC3 gene for SGBS is not routinely available in South Africa.  
Outcomes: 
SGBS is inherited, and thus if a disease causing mutation is found there will be implications 
for the family. This project could also result in the availability of diagnostic testing, and later 
on prenatal testing.  
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Breakdown of funding needed: 
AIM 2: Molecular investigations 
Primers, PCR, sequencing of the 8 exons of GPC3 :                                                                 
R 16 000.00 
Printing, binding and miscellaneous costs: 
Printing:                                                                                                                                           
R 600.00 
Miscellaneous:                                                                                                                               
R 400.00 
 TOTAL (estimated cost)                                                                                                               
R 17 000.00 
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5.12 Appendix 9 
 
 
